

# The future of cancer treatment: immunomodulation, CA immunotherapy

Nature Reviews Clinical Oncology

13, 273-290

DOI: [10.1038/nrclinonc.2016.25](https://doi.org/10.1038/nrclinonc.2016.25)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Combining immunotherapy and radiation therapy for small cell lung cancer and thymic tumors. <i>Translational Lung Cancer Research</i> , 2007, 6, 186-195.	1.3	13
2	Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories. <i>International Journal of Molecular Sciences</i> , 2016, 17, 651.	1.8	20
3	Development of Novel Immunotherapies for Multiple Myeloma. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1506.	1.8	22
4	A Well-Controlled Experimental System to Study Interactions of Cytotoxic T Lymphocytes with Tumor Cells. <i>Frontiers in Immunology</i> , 2016, 7, 326.	2.2	22
5	T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 2016, 7, 353.	2.2	77
6	Novel Immunotherapeutic Approaches for Head and Neck Squamous Cell Carcinoma. <i>Cancers</i> , 2016, 8, 87.	1.7	30
7	Patient-derived xenografts: a relevant preclinical model for drug development. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016, 35, 189.	3.5	109
8	Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16024.	2.0	17
9	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities. <i>Immunotherapy</i> , 2016, 8, 1393-1404.	1.0	8
11	Humanized Mouse Xenograft Models: Narrowing the Tumorâ€™s Microenvironment Gap. <i>Cancer Research</i> , 2016, 76, 6153-6158.	0.4	189
12	Regulatory circuits of T cell function in cancer. <i>Nature Reviews Immunology</i> , 2016, 16, 599-611.	10.6	445
13	Heralding a new paradigm in 3D tumor modeling. <i>Biomaterials</i> , 2016, 108, 197-213.	5.7	127
14	IL-2, IL-7, and IL-15: Multistage regulators of CD4+ T helper cell differentiation. <i>Experimental Hematology</i> , 2016, 44, 799-808.	0.2	57
15	Emerging Strategies for Developing Next-Generation Protein Therapeutics for Cancer Treatment. <i>Trends in Pharmacological Sciences</i> , 2016, 37, 993-1008.	4.0	156
16	Overcoming resistance to checkpoint blockade therapy by targeting PI3KÎ³ in myeloid cells. <i>Nature</i> , 2016, 539, 443-447.	13.7	661
17	Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. <i>Trends in Molecular Medicine</i> , 2016, 22, 1000-1011.	3.5	60
18	T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. <i>Journal of Hematology and Oncology</i> , 2016, 9, 116.	6.9	201
19	NLRC5, a promising new entry in tumor immunology. , 2016, 4, 39.		21

#	ARTICLE	IF	CITATIONS
20	Immunological Mechanisms in Breast Cancer - from Bench to Bedside. <i>Breast Care</i> , 2016, 11, 93-94.	0.8	0
21	Bioprinting towards Physiologically Relevant Tissue Models for Pharmaceuticals. <i>Trends in Biotechnology</i> , 2016, 34, 722-732.	4.9	186
22	Exosomes: novel implications in diagnosis and treatment of gastrointestinal cancer. <i>Langenbeck's Archives of Surgery</i> , 2016, 401, 1097-1110.	0.8	26
23	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 115-128.	12.5	95
24	Integrated analysis of somatic mutations and immune microenvironment in malignant pleural mesothelioma. <i>Oncolmmunology</i> , 2017, 6, e1278330.	2.1	54
25	Cell-Based Therapeutics: Making a Faustian Pact with Biology. <i>Trends in Molecular Medicine</i> , 2017, 23, 104-115.	3.5	9
26	Improved Targeting of Cancers with Nanotherapeutics. <i>Methods in Molecular Biology</i> , 2017, 1530, 13-37.	0.4	11
27	Let This Be Our New Year's Pledge. <i>Oncologist</i> , 2017, 22, 1-2.	1.9	42
28	Translation and Clinical Development of Bispecific Tâ€cell Engaging Antibodies for Cancer Treatment. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 101, 634-645.	2.3	72
29	The expanding role of immunotherapy. <i>Cancer Treatment Reviews</i> , 2017, 54, 74-86.	3.4	100
30	Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 41-54.	3.3	55
31	Oncolytic viral therapy for pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 94-103.	0.8	34
32	NKG2D Ligandâ€Targeted Bispecific T-Cell Engagers Lead to Robust Antitumor Activity against Diverse Human Tumors. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1335-1346.	1.9	17
33	Harnessing combined p19Arf and interferon-beta gene transfer as an inducer of immunogenic cell death and mediator of cancer immunotherapy. <i>Cell Death and Disease</i> , 2017, 8, e2784-e2784.	2.7	10
34	Use of precision methods to accelerate drug development in oncology. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 109-120.	0.4	0
35	In silico polypharmacology of natural products. <i>Briefings in Bioinformatics</i> , 2018, 19, 1153-1171.	3.2	95
36	Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment. <i>Protein and Cell</i> , 2017, 8, 896-925.	4.8	59
37	HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?. <i>Oncolmmunology</i> , 2017, 6, e1295202.	2.1	84

#	ARTICLE	IF	CITATIONS
38	PBMC activation via the ERK and STAT signaling pathways enhances the anti-tumor activity of Staphylococcal enterotoxin A. <i>Molecular and Cellular Biochemistry</i> , 2017, 434, 75-87.	1.4	6
39	Landscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management. <i>Cancer Research</i> , 2017, 77, 3666-3671.	0.4	93
40	Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine. <i>Genes and Diseases</i> , 2017, 4, 43-63.	1.5	451
41	Characterization of MK-4166, a Clinical Agonistic Antibody That Targets Human GITR and Inhibits the Generation and Suppressive Effects of T Regulatory Cells. <i>Cancer Research</i> , 2017, 77, 4378-4388.	0.4	56
42	CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells. <i>Frontiers of Medicine</i> , 2017, 11, 554-562.	1.5	170
43	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017, 545, 452-456.	13.7	643
44	Bio-Orthogonal Mediated Nucleic Acid Transfection of Cells via Cell Surface Engineering. <i>ACS Central Science</i> , 2017, 3, 489-500.	5.3	20
45	Immune Checkpoint Blockade and Gastric Cancer. , 2017, , 115-130.		2
46	Delivering safer immunotherapies for cancer. <i>Advanced Drug Delivery Reviews</i> , 2017, 114, 79-101.	6.6	233
47	Epithelialâ€mesenchymal transition in cancer metastasis through the lymphatic system. <i>Molecular Oncology</i> , 2017, 11, 781-791.	2.1	106
48	Manufacture of CAR-T cells in the body. <i>Nature Biotechnology</i> , 2017, 35, 520-521.	9.4	16
49	Unravelling the biology of SCLC: implications for therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 549-561.	12.5	336
50	Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Death-Ligand 1 (PD-1/PD-L1) Interaction via Transiently Induced Protein States and Dimerization of PD-L1. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 5857-5867.	2.9	242
51	Beyond checkpoint inhibition â€“ Immunotherapeutical strategies in combination with radiation. <i>Clinical and Translational Radiation Oncology</i> , 2017, 2, 29-35.	0.9	27
52	Delivery technologies for genome editing. <i>Nature Reviews Drug Discovery</i> , 2017, 16, 387-399.	21.5	422
53	Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. , 2017, 5, 28.		154
54	T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy. <i>Laboratory Investigation</i> , 2017, 97, 669-697.	1.7	167
55	Cancer Immunotherapy: Whence and Whither. <i>Molecular Cancer Research</i> , 2017, 15, 635-650.	1.5	30

#	ARTICLE	IF	CITATIONS
56	Antibodies Create Killer Bonds in Myeloma. <i>Cancer Cell</i> , 2017, 31, 305-307.	7.7	2
57	Coupling of Immunostimulants to Live Cells through Metabolic Glycoengineering and Bioorthogonal Click Chemistry. <i>Bioconjugate Chemistry</i> , 2017, 28, 1151-1165.	1.8	10
58	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines. , 2017, 178, 31-47.		89
59	The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. <i>Journal of Hepatology</i> , 2017, 67, 173-183.	1.8	165
60	Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinic. <i>Endocrine-Related Cancer</i> , 2017, 24, T83-T96.	1.6	63
61	Immune deficiency augments the prevalence of p53 loss of heterozygosity in spontaneous tumors but not bi-directional loss of heterozygosity in bone marrow progenitors. <i>International Journal of Cancer</i> , 2017, 140, 1364-1369.	2.3	2
62	Adenovirotherapy Delivering Cytokine and Checkpoint Inhibitor Augments CAR T Cells against Metastatic Head and Neck Cancer. <i>Molecular Therapy</i> , 2017, 25, 2440-2451.	3.7	151
63	Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. <i>Advanced Materials</i> , 2017, 29, 1703969.	11.1	392
64	Gene editing in T cell therapy. <i>Journal of Genetics and Genomics</i> , 2017, 44, 415-422.	1.7	15
65	Antigen receptor repertoire profiling from RNA-seq data. <i>Nature Biotechnology</i> , 2017, 35, 908-911.	9.4	243
66	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 1420-1435.	7.7	507
67	ADAR1 expression is associated with tumour-infiltrating lymphocytes in triple-negative breast cancer. <i>Tumor Biology</i> , 2017, 39, 101042831773481.	0.8	18
68	Mechanisms regulating T-cell infiltration and activity in solid tumors. <i>Annals of Oncology</i> , 2017, 28, xii18-xii32.	0.6	276
69	MicroRNAs in the Diagnosis and Treatment of Cancer. <i>Immunological Investigations</i> , 2017, 46, 880-897.	1.0	52
70	Checkpoint immunotherapy in head and neck cancers. <i>Cancer and Metastasis Reviews</i> , 2017, 36, 475-489.	2.7	33
71	Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia. <i>Journal of Autoimmunity</i> , 2017, 85, 141-152.	3.0	14
72	Novel Immunotherapies for Multiple Myeloma. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 344-357.	1.2	30
73	Radiotherapy in combination with immune checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2017, 29, 105-111.	1.1	14

#	ARTICLE	IF	CITATIONS
74	The clinical value of combination of immune checkpoint inhibitors in cancer patients: A meta-analysis of efficacy and safety. <i>International Journal of Cancer</i> , 2017, 141, 2562-2570.	2.3	35
75	Supramolecular catalysis and dynamic assemblies for medicine. <i>Chemical Society Reviews</i> , 2017, 46, 6470-6479.	18.7	137
76	Combination of anti-CD 4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation. <i>Cancer Science</i> , 2017, 108, 1967-1973.	1.7	3
77	Nanomaterials for cancer immunotherapy. <i>Biomaterials</i> , 2017, 148, 16-30.	5.7	226
78	Bridging Bio-Nano Science and Cancer Nanomedicine. <i>ACS Nano</i> , 2017, 11, 9594-9613.	7.3	304
79	Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. <i>Angewandte Chemie</i> , 2017, 129, 13920-13923.	1.6	13
80	Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy. <i>Immunotherapy</i> , 2017, 9, 851-861.	1.0	8
81	Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy. <i>Immunotherapy</i> , 2017, 9, 837-849.	1.0	1
82	Bioactive Macrocyclic Inhibitors of the PD-1/PD-L1 Immune Checkpoint. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 13732-13735.	7.2	131
83	Computational study on the origin of the cancer immunotherapeutic potential of B and T cell epitope peptides. <i>Molecular BioSystems</i> , 2017, 13, 2310-2322.	2.9	2
84	Atezolizumab for the treatment of non-small cell lung cancer. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 935-945.	1.3	34
85	Oncolytic virus-induced cell death and immunity: a match made in heaven?. <i>Journal of Leukocyte Biology</i> , 2017, 102, 631-643.	1.5	35
86	A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer. <i>EBioMedicine</i> , 2017, 22, 58-67.	2.7	115
88	Structural Biology of the Immune Checkpoint Receptor PD-1 and Its Ligands PD-L1/PD-L2. <i>Structure</i> , 2017, 25, 1163-1174.	1.6	253
89	Lectin from inflorescences of ornamental crop <i>Alpinia purpurata</i> acts on immune cells to promote Th1 and Th17 responses, nitric oxide release, and lymphocyte activation. <i>Biomedicine and Pharmacotherapy</i> , 2017, 94, 865-872.	2.5	16
90	Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. <i>BMJ Open</i> , 2017, 7, e017075.	0.8	43
91	Modulating host immune responses to fight invasive fungal infections. <i>Current Opinion in Microbiology</i> , 2017, 40, 95-103.	2.3	32
92	Anti-SIRP $\alpha$ antibody immunotherapy enhances neutrophil and macrophage antitumor activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E10578-E10585.	3.3	223

#	ARTICLE	IF	CITATIONS
93	Young donor white blood cell immunotherapy induces extensive tumor necrosis in advanced-stage solid tumors. <i>Heliyon</i> , 2017, 3, e00438.	1.4	9
94	Inhibitors of the Kynurenine Pathway. <i>Topics in Medicinal Chemistry</i> , 2017, , 371-371.	0.4	2
95	Molecular Dissection of CD8 + T-Cell Dysfunction. <i>Trends in Immunology</i> , 2017, 38, 567-576.	2.9	51
96	Bio-inks for 3D bioprinting: recent advances and future prospects. <i>Polymer Chemistry</i> , 2017, 8, 4451-4471.	1.9	256
97	Continuous immunotypes describe human immune variation and predict diverse responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E6097-E6106.	3.3	104
98	Chimeric antigen receptor T-cells for B-cell malignancies. <i>Translational Research</i> , 2017, 187, 59-82.	2.2	22
99	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. <i>American Journal of Roentgenology</i> , 2017, 209, 567-575.	1.0	26
100	Translating antibody directed enzyme prodrug therapy (ADEPT) and prospects for combination. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1-13.	1.4	37
101	5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 415-426.	2.0	44
102	Emerging links among Chromosome Instability (CIN), cancer, and aging. <i>Molecular Carcinogenesis</i> , 2017, 56, 791-803.	1.3	22
103	Optogenetic Immunomodulation: Shedding Light on Antitumor Immunity. <i>Trends in Biotechnology</i> , 2017, 35, 215-226.	4.9	77
104	<i>In Vivo</i> Expansion of Melanoma-Specific T Cells Using Microneedle Arrays Coated with Immune-Polyelectrolyte Multilayers. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 195-205.	2.6	77
105	Lymphoma: current status of clinical and preclinical imaging with radiolabeled antibodies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 517-532.	3.3	21
106	The role of dendritic cells in cancer. <i>Seminars in Immunopathology</i> , 2017, 39, 307-316.	2.8	76
107	A PEGylated hyaluronic acid conjugate for targeted cancer immunotherapy. <i>Journal of Controlled Release</i> , 2017, 267, 181-190.	4.8	41
108	The revolution of lung cancer treatment: from vaccines, to immune checkpoint inhibitors, to chimeric antigen receptor T therapy. <i>Biotarget</i> , 0, 1, 7-7.	0.5	11
109	Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. <i>Cancer Management and Research</i> , 2017, Volume 9, 249-258.	0.9	11
110	Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment. <i>Cancers</i> , 2017, 9, 24.	1.7	31

#	ARTICLE	IF	CITATIONS
111	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
112	Natural Killer Group 2D Ligand Depletion Reconstitutes Natural Killer Cell Immunosurveillance of Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2017, 8, 387.	2.2	38
113	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	2.2	43
114	The Potential of Donor T-Cell Repertoires in Neoantigen-Targeted Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1718.	2.2	36
115	New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness. <i>Frontiers in Immunology</i> , 2017, 8, 1804.	2.2	54
116	New Chimeric Antigen Receptor Design for Solid Tumors. <i>Frontiers in Immunology</i> , 2017, 8, 1934.	2.2	23
117	Changes of peripheral lymphocyte subsets and cytokine environment during aging and deteriorating gastrointestinal tract health status. <i>Oncotarget</i> , 2017, 8, 60764-60777.	0.8	6
118	Advances in the Treatment of Primary Brain Tumors: The Realm of Immunotherapy. , 0, , .		0
119	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. <i>Oncotarget</i> , 2017, 8, 72167-72181.	0.8	221
120	Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer. <i>Oncotarget</i> , 2017, 8, 113345-113359.	0.8	61
121	Antiangiogenic therapy and immune checkpoint blockade go hand in hand. <i>Annals of Translational Medicine</i> , 2017, 5, 497-497.	0.7	21
122	Immunotherapy for Brain Tumors. <i>Journal of Clinical Oncology</i> , 2017, 35, 2450-2456.	0.8	112
123	The role of mouse models in translational cancer research: present and future directions. <i>Translational Medicine Reports</i> , 2017, 1, .	0.8	1
124	Enhanced Cellular Ablation by Attenuating Hypoxia Status and Reprogramming Tumor-Associated Macrophages via NIR Light-Responsive Upconversion Nanocrystals. <i>Bioconjugate Chemistry</i> , 2018, 29, 928-938.	1.8	71
125	Introducing a New Series: Immunotherapy Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 1773-1774.	3.2	4
126	N-Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen-Presenting Cells through Dectin-1 and Dectin-2. <i>Angewandte Chemie</i> , 2018, 130, 3191-3196.	1.6	3
127	A Dual Immunotherapy Nanoparticle Improves T-Cell Activation and Cancer Immunotherapy. <i>Advanced Materials</i> , 2018, 30, e1706098.	11.1	130
128	Obesity induced T cell dysfunction and implications for cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2018, 51, 181-186.	2.4	52



#	ARTICLE	IF	CITATIONS
129	Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents. <i>Liver International</i> , 2018, 38, 976-987.	1.9	166
131	A review of microfluidic approaches for investigating cancer extravasation during metastasis. <i>Microsystems and Nanoengineering</i> , 2018, 4, .	3.4	115
132	Immunostimulation and Immunosuppression: Nanotechnology on the Brink. <i>Small Methods</i> , 2018, 2, 1700347.	4.6	32
133	The research status of immune checkpoint blockade by anti-CTLA4 and anti-PD1/PD-I1 antibodies in tumor immunotherapy in China. <i>Medicine (United States)</i> , 2018, 97, e0276.	0.4	5
134	Induction of necrotic cell death and activation of STING in the tumor microenvironment via cationic silica nanoparticles leading to enhanced antitumor immunity. <i>Nanoscale</i> , 2018, 10, 9311-9319.	2.8	77
135	Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. <i>Oncolimmunology</i> , 2018, 7, e1433982.	2.1	38
136	Cancer immunotherapy beyond immune checkpoint inhibitors. <i>Journal of Hematology and Oncology</i> , 2018, 11, 8.	6.9	174
137	Synthetic Immunobiotics: A Future Success Story in Small Molecule-Based Immunotherapy?. <i>ACS Infectious Diseases</i> , 2018, 4, 664-672.	1.8	7
138	Nanoparticle-Mediated Trapping of Wnt Family Member 5A in Tumor Microenvironments Enhances Immunotherapy for B-Raf Proto-Oncogene Mutant Melanoma. <i>ACS Nano</i> , 2018, 12, 1250-1261.	7.3	76
139	IDO1 in cancer: a Gemini of immune checkpoints. <i>Cellular and Molecular Immunology</i> , 2018, 15, 447-457.	4.8	266
140	Abscopal effects of radiotherapy and combined mRNA-based immunotherapy in a syngeneic, OVA-expressing thymoma mouse model. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 653-662.	2.0	11
141	Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. <i>Autoimmunity Reviews</i> , 2018, 17, 284-289.	2.5	149
142	Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. <i>Cancer</i> , 2018, 124, 2086-2103.	2.0	141
143	Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and TIGIT) in triple-negative breast cancer. <i>Journal of Clinical Investigation</i> , 2018, 128, 1000-1010.	2.3	85
144	The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 477-485.	0.9	16
145	Next-generation immunotherapies for lymphoma: one foot in the future. <i>Annals of Oncology</i> , 2018, 29, 588-601.	0.6	13
146	Carboxyanhydride Polymerization of Glycopolypeptides That Activate Antigen-Presenting Cells through Dectin-1 and Dectin-2. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 3137-3142.	7.2	51
147	Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 45-53.	2.7	30

#	ARTICLE	IF	CITATIONS
148	Progress in Science, Progress in Society. , 2018, , .		0
149	Innate Immune Receptors in the Regulation of Tumor Immunity. , 2018, , 407-427.		0
150	Nanotechnology Strategies To Advance Outcomes in Clinical Cancer Care. ACS Nano, 2018, 12, 24-43.	7.3	192
151	The promising role of monoclonal antibodies for immunotherapy of the HIV-associated cancer, non-Hodgkin lymphoma. International Reviews of Immunology, 2018, 37, 165-173.	1.5	4
152	Cholesterol Esterification Enzyme Inhibition Enhances Antitumor Effects of Human Chimeric Antigen Receptors Modified T Cells. Journal of Immunotherapy, 2018, 41, 45-52.	1.2	23
153	Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold. ACS Medicinal Chemistry Letters, 2018, 9, 131-136.	1.3	29
154	New Perspectives in Genetic Therapies. , 2018, , 71-78.		0
155	Improving immune-vascular crosstalk for cancer immunotherapy. Nature Reviews Immunology, 2018, 18, 195-203.	10.6	340
156	Nanocage-therapeutics Prevailing Phagocytosis and Immunogenic Cell Death Awakens Immunity against Cancer. Advanced Materials, 2018, 30, 1705581.	11.1	55
157	Blockade of BAFF Receptor BR3 on T Cells Enhances Their Activation and Cytotoxicity. Journal of Immunotherapy, 2018, 41, 213-223.	1.2	7
158	The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival. Oncoimmunology, 2018, 7, e1465166.	2.1	36
159	PD-L1-independent Mechanisms Control the Resistance of Melanoma to CD4+ T Cell Adoptive Immunotherapy. Journal of Immunology, 2018, 200, 3304-3311.	0.4	6
160	Armed oncolytic viruses: A kick-start for anti-tumor immunity. Cytokine and Growth Factor Reviews, 2018, 41, 28-39.	3.2	110
161	Novel targeted therapies and immunotherapy for advanced thyroid cancers. Molecular Cancer, 2018, 17, 51.	7.9	168
162	Programmed cell death ligand-1 expression in tumor and immune cells is associated with better patient outcome and decreased tumor-infiltrating lymphocytes in uveal melanoma. Modern Pathology, 2018, 31, 1201-1210.	2.9	19
163	The future impacts of non-targeted effects. International Journal of Radiation Biology, 2018, 94, 727-736.	1.0	12
164	Advances in immunotherapy for acute myeloid leukemia. Future Oncology, 2018, 14, 963-978.	1.1	32
165	Single-cell technologies for profiling T cells to enable monitoring of immunotherapies. Current Opinion in Chemical Engineering, 2018, 19, 142-152.	3.8	11

#	ARTICLE	IF	CITATIONS
166	Rapid Advances in Immunotherapy to Treat Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 540-544.	2.3	64
167	A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VX001, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer. <i>Oncotarget</i> , 2018, 9, e1303584.	2.1	41
168	Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer. <i>Journal of Cellular Physiology</i> , 2018, 233, 2032-2057.	2.0	116
169	Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines. <i>Advanced Healthcare Materials</i> , 2018, 7, 1700432.	3.9	30
170	Axicabtagene ciloleucel, a first-in-class CAR T cell therapy for aggressive NHL. <i>Leukemia and Lymphoma</i> , 2018, 59, 1785-1796.	0.6	102
171	Phase I/II trial of combined kyphoplasty and intraoperative radiotherapy in spinal metastases. <i>Spine Journal</i> , 2018, 18, 776-781.	0.6	15
172	Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment. <i>MAbs</i> , 2018, 10, 1-17.	2.6	35
173	Polyester micelles for drug delivery and cancer theranostics: Current achievements, progresses and future perspectives. <i>Materials Science and Engineering C</i> , 2018, 83, 218-232.	3.8	68
174	Host-directed therapies for bacterial and viral infections. <i>Nature Reviews Drug Discovery</i> , 2018, 17, 35-56.	21.5	512
175	Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 47-60.	2.0	29
176	Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2018, 13, 16-26.	0.5	72
177	Cellular Bioparticulates with Therapeutics for Cancer Immunotherapy. <i>Bioconjugate Chemistry</i> , 2018, 29, 702-708.	1.8	17
178	Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy. <i>Stem Cells</i> , 2018, 36, 134-145.	1.4	48
179	Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer. <i>Journal of Immunotherapy</i> , 2018, 41, 130-140.	1.2	38
180	CAR T cell therapy for multiple myeloma: where are we now and where are we headed?. <i>Leukemia and Lymphoma</i> , 2018, 59, 2056-2067.	0.6	50
182	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. <i>Current Cancer Research</i> , 2018, , 1-28.	0.2	0
183	Pharmacokinetics and Pharmacodynamics of Immunotherapy. <i>Current Cancer Research</i> , 2018, , 29-67.	0.2	6
184	Immune checkpoint inhibitors: new strategies to checkmate cancer. <i>Clinical and Experimental Immunology</i> , 2018, 191, 133-148.	1.1	57

#	ARTICLE	IF	CITATIONS
185	Vaccination with human amniotic epithelial cells confer effective protection in a murine model of Colon adenocarcinoma. <i>International Journal of Cancer</i> , 2018, 142, 1453-1466.	2.3	11
186	Wnt pathway activator TWS119 enhances the proliferation and cytolytic activity of human $\gamma\delta$ T cells against colon cancer. <i>Experimental Cell Research</i> , 2018, 362, 63-71.	1.2	20
187	Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes. <i>Cancer Immunology Research</i> , 2018, 6, 59-68.	1.6	26
188	Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 393-401.	2.0	15
189	Combination immunotherapy with Survivin and luteinizing hormone-releasing hormone fusion protein in murine breast cancer model. <i>World Journal of Clinical Oncology</i> , 2018, 9, 188-199.	0.9	3
190	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. <i>Translational Lung Cancer Research</i> , 2018, 7, 50-68.	1.3	96
191	Multivariate Entropy Characterizes the Gene Expression and Protein-Protein Networks in Four Types of Cancer. <i>Entropy</i> , 2018, 20, 154.	1.1	4
192	Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy. <i>International Journal of Oncology</i> , 2018, 53, 1193-1203.	1.4	41
193	Targeted Therapies in Platinum-Resistant Ovarian Cancer: Advances in Immunotherapy Combination Strategies. , 0, , .		1
194	Novel 'Stereoscopic Response' Strategy Can Be Used in Combination Therapy. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2018, 35, 369-390.	1.2	2
195	The adverse kidney effects of cancer immunotherapies. <i>Journal of Onco-Nephrology</i> , 2018, 2, 56-68.	0.3	2
196	Immunostimulatory Effect of <i>Zanthoxylum schinifolium</i> -Based Complex Oil Prepared by Supercritical Fluid Extraction in Splenocytes and Cyclophosphamide-Induced Immunosuppressed Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2018, 2018, 1-10.	0.5	11
197	Indocyanine Green-Conjugated Magnetic Prussian Blue Nanoparticles for Synchronous Photothermal/Photodynamic Tumor Therapy. <i>Nano-Micro Letters</i> , 2018, 10, 74.	14.4	81
198	CD39 as a marker of pathogenic CD8+ T cells in cancer and other chronic inflammatory diseases. <i>Oncoscience</i> , 2018, 5, 65-66.	0.9	3
199	A Computational Approach Identifies Immunogenic Features of Prognosis in Human Cancers. <i>Frontiers in Immunology</i> , 2018, 9, 3017.	2.2	8
200	A Novel Small Peptide Inhibitor of NF $\kappa$ B, RH10, Blocks Oxidative Stress-Dependent Phenotypes in Cancer. <i>Oxidative Medicine and Cellular Longevity</i> , 2018, 2018, 1-9.	1.9	4
201	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. <i>Journal of Clinical Medicine</i> , 2018, 7, 542.	1.0	64
202	Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 306-311.	2.0	18

#	ARTICLE	IF	CITATIONS
203	Oncolytic virus immunotherapy: future prospects for oncology. , 2018, 6, 140.		197
204	Immunomodulators in Autoimmunity and Viral Infections. Journal of Clinical & Cellular Immunology, 2018, 09, .	1.5	5
205	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. Cancer Immunology Research, 2018, 6, 1445-1452.	1.6	132
206	Nanomaterial Manipulation of Immune Microenvironment in the Diseased Liver. Advanced Functional Materials, 2019, 29, 1805760.	7.8	13
207	Checkpoint Inhibition in Myeloma: Opportunities and Challenges. Frontiers in Immunology, 2018, 9, 2204.	2.2	45
208	Ruthenium pyridyl thiocyanate complex increased the production of pro-inflammatory TNF $\alpha$ and IL1 $\beta$ cytokines by the LPS stimulated mammalian macrophages in vitro. Molecular Biology Reports, 2018, 45, 2307-2312.	1.0	16
209	The role of radiology in the evaluation of the immunotherapy efficacy. Journal of Thoracic Disease, 2018, 10, S1438-S1446.	0.6	22
210	A neoepitope derived from a novel human germline APC gene mutation in familial adenomatous polyposis shows selective immunogenicity. PLoS ONE, 2018, 13, e0203845.	1.1	4
211	Role of noninvasive molecular imaging in determining response. Advances in Radiation Oncology, 2018, 3, 534-547.	0.6	25
212	NOTCH Signaling in T-Cell-Mediated Anti-Tumor Immunity and T-Cell-Based Immunotherapies. Frontiers in Immunology, 2018, 9, 1718.	2.2	47
213	The DNA damage response in immunotherapy and radiation. Advances in Radiation Oncology, 2018, 3, 527-533.	0.6	24
214	Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy. , 2018, 6, 88.		41
215	Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond. Applied Microbiology and Biotechnology, 2018, 102, 9449-9470.	1.7	54
216	Immuno-MALDI (iMALDI) mass spectrometry for the analysis of proteins in signaling pathways. Expert Review of Proteomics, 2018, 15, 701-708.	1.3	8
217	Structural insights and influence of V599 mutations on the overall dynamics of <i>BRAF</i> protein against its kinase domains. Integrative Biology (United Kingdom), 2018, 10, 646-657.	0.6	10
218	Trial watch: Peptide-based vaccines in anticancer therapy. OncoImmunology, 2018, 7, e1511506.	2.1	121
219	Prognostic modeling of the immune-centric transcriptome reveals interleukin signaling candidates contributing to differential patient outcomes. Carcinogenesis, 2018, 39, 1447-1454.	1.3	4
220	Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment. Frontiers in Immunology, 2018, 9, 2103.	2.2	56

#	ARTICLE	IF	CITATIONS
221	Human Endogenous Retrovirus K in the Crosstalk Between Cancer Cells Microenvironment and Plasticity: A New Perspective for Combination Therapy. <i>Frontiers in Microbiology</i> , 2018, 9, 1448.	1.5	26
222	Outlook and future of inner ear therapy. <i>Hearing Research</i> , 2018, 368, 127-135.	0.9	33
223	AML: exposed and exploited?. <i>Blood</i> , 2018, 131, 8-10.	0.6	3
224	Increased exhausted CD8 <sup>+</sup> T cells with programmed death-1, T cell immunoglobulin and mucin domain-containing 3 phenotype in patients with multiple myeloma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e266-e274.	0.7	30
225	Patient-derived tumor organoids for prediction of cancer treatment response. <i>Seminars in Cancer Biology</i> , 2018, 53, 258-264.	4.3	122
226	Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2039-2052.	3.0	121
227	Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". <i>Cancer Treatment Reviews</i> , 2018, 69, 121-131.	3.4	46
228	Immune ligands for cytotoxic T Lymphocytes CTLs in cancer stem cells CSCs. <i>Frontiers in Bioscience - Landmark</i> , 2018, 23, 563-583.	3.0	6
229	Current status and future directions of cancer immunotherapy. <i>Journal of Cancer</i> , 2018, 9, 1773-1781.	1.2	273
230	Tumor-infiltrating lymphocyte as a prognostic biomarker in stage IV colorectal cancer should take into account the metastatic status and operation modality. <i>Cancer Management and Research</i> , 2018, Volume 10, 1365-1375.	0.9	17
231	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies. <i>Frontiers in Immunology</i> , 2018, 9, 1740.	2.2	155
232	Immuno-Oncology: Emerging Targets and Combination Therapies. <i>Frontiers in Oncology</i> , 2018, 8, 315.	1.3	244
233	Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens. <i>Nature Communications</i> , 2018, 9, 2896.	5.8	39
234	Recombinant <i>Listeria</i> promotes tumor rejection by CD8 <sup>+</sup> T cell-dependent remodeling of the tumor microenvironment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 8179-8184.	3.3	60
235	Tumor Necrosis Factor $\alpha$ and Regulatory T Cells in Oncoimmunology. <i>Frontiers in Immunology</i> , 2018, 9, 444.	2.2	139
236	Toward a Tiered Model to Share Clinical Trial Data and Samples in Precision Oncology. <i>Frontiers in Medicine</i> , 2018, 5, 6.	1.2	14
237	Hydrogels-Assisted Cell Engraftment for Repairing the Stroke-Damaged Brain: Chimera or Reality. <i>Polymers</i> , 2018, 10, 184.	2.0	28
238	Traceable Bioinspired Nanoparticle for the Treatment of Metastatic Breast Cancer via NIR-Triggered Intracellular Delivery of Methylene Blue and Cisplatin. <i>Advanced Materials</i> , 2018, 30, e1802378.	11.1	73

#	ARTICLE	IF	CITATIONS
239	Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 38.	1.8	171
240	Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses. <i>Cancer Cell International</i> , 2018, 18, 9.	1.8	16
241	Measuring multiple parameters of CD8+ tumor-infiltrating lymphocytes in human cancers by image analysis. , 2018, 6, 20.		82
242	ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. <i>Nature Medicine</i> , 2018, 24, 556-562.	15.2	372
243	Non-enzymolytic adenosine barcode-mediated dual signal amplification strategy for ultrasensitive protein detection using LC-MS/MS. <i>Mikrochimica Acta</i> , 2018, 185, 293.	2.5	1
244	Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism. <i>Scientific Reports</i> , 2018, 8, 7205.	1.6	71
245	Immune-related adverse events from combination immunotherapy in cancer patients: A comprehensive meta-analysis of randomized controlled trials. <i>International Immunopharmacology</i> , 2018, 63, 292-298.	1.7	83
246	Biomaterial-assisted targeted modulation of immune cells in cancer treatment. <i>Nature Materials</i> , 2018, 17, 761-772.	13.3	352
247	BET Bromodomain Inhibition Cooperates with PD-1 Blockade to Facilitate Antitumor Response in <i>Kras</i> -Mutant Non-Small Cell Lung Cancer. <i>Cancer Immunology Research</i> , 2018, 6, 1234-1245.	1.6	80
248	Tumor Antigen Escape from CAR T-cell Therapy. <i>Cancer Discovery</i> , 2018, 8, 1219-1226.	7.7	661
249	Synthetic vaccine particles for durable cytolytic T lymphocyte responses and anti-tumor immunotherapy. <i>PLoS ONE</i> , 2018, 13, e0197694.	1.1	17
250	Nanotechnology Approaches to Improving Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2018, 139, 35-56.	1.9	33
251	Targeting Necroptosis in Antitumor Therapy. , 2019, , 275-285.		1
252	Development of a PD-L1-Expressing Orthotopic Liver Cancer Model: Implications for Immunotherapy for Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2019, 8, 155-171.	4.2	25
253	Applications and advances of CRISPR-Cas9 in cancer immunotherapy. <i>Journal of Medical Genetics</i> , 2019, 56, 4-9.	1.5	39
254	Bacteria-free minicircle DNA system to generate integration-free CAR-T cells. <i>Journal of Medical Genetics</i> , 2019, 56, 10-17.	1.5	17
255	Tumor infiltrating lymphocytes expanded from pediatric neuroblastoma display heterogeneity of phenotype and function. <i>PLoS ONE</i> , 2019, 14, e0216373.	1.1	19
256	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment—Review. <i>Frontiers in Immunology</i> , 2019, 10, 2043.	2.2	7

#	ARTICLE	IF	CITATIONS
257	Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination. <i>Frontiers in Oncology</i> , 2019, 9, 811.	1.3	47
258	Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?. <i>Haematologica</i> , 2019, 104, 1521-1531.	1.7	18
259	Mannose-Modified Multi-Walled Carbon Nanotubes as a Delivery Nanovector Optimizing the Antigen Presentation of Dendritic Cells. <i>ChemistryOpen</i> , 2019, 8, 915-921.	0.9	19
260	Notch signaling in breast cancer: From pathway analysis to therapy. <i>Cancer Letters</i> , 2019, 461, 123-131.	3.2	69
261	Japan oncology market overview: Current and future perspectives. <i>Journal of Generic Medicines</i> , 2019, 15, 104-114.	0.0	1
262	Immune checkpoint inhibitors for hepatocellular carcinoma. <i>Cancer</i> , 2019, 125, 3312-3319.	2.0	90
263	Synergistic combination of oncolytic virotherapy with CAR T-cell therapy. <i>Progress in Molecular Biology and Translational Science</i> , 2019, 164, 217-292.	0.9	15
264	The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 1574.	2.2	45
265	Anti-CD40 mAb enhanced efficacy of anti-PD1 against osteosarcoma. <i>Journal of Bone Oncology</i> , 2019, 17, 100245.	1.0	17
266	Differential Immunomodulatory Activities of Schiff Base Complexes Depending on their Metal Conjugation. <i>Inflammation</i> , 2019, 42, 1878-1885.	1.7	15
267	Selectively targeting tumor-associated macrophages and tumor cells with polymeric micelles for enhanced cancer chemo-immunotherapy. <i>Journal of Controlled Release</i> , 2019, 313, 42-53.	4.8	78
268	Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges. <i>Cancers</i> , 2019, 11, 1554.	1.7	73
269	Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses. <i>Chemical Society Reviews</i> , 2019, 48, 5506-5526.	18.7	209
270	Immune effector monocyte-neutrophil cooperation induced by the primary tumor prevents metastatic progression of breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21704-21714.	3.3	66
271	SHP-2 in Lymphocytes' Cytokine and Inhibitory Receptor Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 2468.	2.2	37
272	Secondary resistance to immunotherapy associated with $\beta$ -catenin pathway activation or PTEN loss in metastatic melanoma. , 2019, 7, 295.		98
273	Quantitative Proteomics and Metabolomics Reveal Biomarkers of Disease as Potential Immunotherapy Targets and Indicators of Therapeutic Efficacy. <i>Theranostics</i> , 2019, 9, 7872-7888.	4.6	27
274	Nanoscale Coordination Polymer Based Nanovaccine for Tumor Immunotherapy. <i>ACS Nano</i> , 2019, 13, 13127-13135.	7.3	83



#	ARTICLE	IF	CITATIONS
275	Targeted Therapies for Pediatric AML: Gaps and Perspective. <i>Frontiers in Pediatrics</i> , 2019, 7, 463.	0.9	52
276	PD-L1 Expression and Tumor-Infiltrating Lymphocytes in Thymic Epithelial Neoplasms. <i>Journal of Clinical Medicine</i> , 2019, 8, 1833.	1.0	19
277	Constrained Nanoparticles Deliver siRNA and sgRNA to T Cells In Vivo without Targeting Ligands. <i>Advanced Materials</i> , 2019, 31, e1902251.	11.1	99
278	Safety and efficacy of PD-1 blockade-activated multiple antigen-specific cellular therapy alone or in combination with apatinib in patients with advanced solid tumors: a pooled analysis of two prospective trials. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1467-1477.	2.0	19
279	Improving cancer immunotherapy through nanotechnology. <i>Nature Reviews Cancer</i> , 2019, 19, 587-602.	12.8	426
280	The Proteomic Effects of Pulsed Focused Ultrasound on Tumor Microenvironments of Murine Melanoma and Breast Cancer Models. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 3232-3245.	0.7	14
281	Role of CXCR3 signaling in response to anti-PD-1 therapy. <i>EBioMedicine</i> , 2019, 48, 169-177.	2.7	37
282	Molecular Modeling Studies on the Binding Mode of the PD-1/PD-L1 Complex Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4654.	1.8	29
283	Proton transport modeling in a realistic biological environment by using TILDA-V. <i>Scientific Reports</i> , 2019, 9, 14030.	1.6	9
284	In vivo CRISPR screening in CD8 T cells with AAV Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. <i>Nature Biotechnology</i> , 2019, 37, 1302-1313.	9.4	123
285	Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development. <i>Current Oncology Reports</i> , 2019, 21, 2.	1.8	42
286	Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy. <i>Nature Nanotechnology</i> , 2019, 14, 269-278.	15.6	406
287	CRISPR-Cas: a tool for cancer research and therapeutics. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 281-295.	12.5	127
288	Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors. , 2019, 7, 18.		72
289	Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes. <i>Cancers</i> , 2019, 11, 138.	1.7	30
290	Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors. <i>Frontiers in Immunology</i> , 2019, 10, 218.	2.2	43
291	A Viral Nanoparticle Cancer Vaccine Delays Tumor Progression and Prolongs Survival in a HER2 <sup>+</sup> Tumor Mouse Model. <i>Advanced Therapeutics</i> , 2019, 2, 1800139.	1.6	25
292	A comprehensive review on Phyllanthus derived natural products as potential chemotherapeutic and immunomodulators for a wide range of human diseases. <i>Biocatalysis and Agricultural Biotechnology</i> , 2019, 17, 529-537.	1.5	21

#	ARTICLE	IF	CITATIONS
293	Novel Bispecific Aptamer Enhances Immune Cytotoxicity Against MUC1-Positive Tumor Cells by MUC1-CD16 Dual Targeting. <i>Molecules</i> , 2019, 24, 478.	1.7	17
294	Surgery-free injectable macroscale biomaterials for local cancer immunotherapy. <i>Biomaterials Science</i> , 2019, 7, 733-749.	2.6	41
295	Symmetric bis-benzoxazole-based chemicals exerted anti-inflammatory effect on danger signal LPS-stimulated macrophages. <i>Monatshefte für Chemie</i> , 2019, 150, 1137-1146.	0.9	19
296	IFN- $\gamma$ : A cytokine at the right time, is in the right place. <i>Seminars in Immunology</i> , 2019, 43, 101280.	2.7	134
297	Probiotics <i>Lactobacillus reuteri</i> Abrogates Immune Checkpoint Blockade-Associated Colitis by Inhibiting Group 3 Innate Lymphoid Cells. <i>Frontiers in Immunology</i> , 2019, 10, 1235.	2.2	83
298	Immunomodulatory Nanosystems. <i>Advanced Science</i> , 2019, 6, 1900101.	5.6	255
299	Multifunctional Nanoregulator Reshapes Immune Microenvironment and Enhances Immune Memory for Tumor Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1900037.	5.6	94
300	The 6th R of Radiobiology: Reactivation of Anti-Tumor Immune Response. <i>Cancers</i> , 2019, 11, 860.	1.7	75
301	Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. <i>Pharmaceutical Research</i> , 2019, 36, 125.	1.7	46
302	Manipulating Immune Activation of Macrophages by Tuning the Oligonucleotide Composition of Gold Nanoparticles. <i>Bioconjugate Chemistry</i> , 2019, 30, 2032-2037.	1.8	36
303	Immunosuppressive Tumor Microenvironment Status and Histological Grading of Endometrial Carcinoma. <i>Cancer Microenvironment</i> , 2019, 12, 169-179.	3.1	21
304	Recent advances in nanomaterial-based synergistic combination cancer immunotherapy. <i>Chemical Society Reviews</i> , 2019, 48, 3771-3810.	18.7	292
305	Engineering Cell Membrane-Based Nanotherapeutics to Target Inflammation. <i>Advanced Science</i> , 2019, 6, 1900605.	5.6	143
306	P16 expression and its association with PD-L1 expression and FOXP3-positive tumor infiltrating lymphocytes in head and neck squamous cell carcinoma. <i>Molecular and Cellular Toxicology</i> , 2019, 15, 137-143.	0.8	6
307	Turning the Tide Against Regulatory T Cells. <i>Frontiers in Oncology</i> , 2019, 9, 279.	1.3	47
308	Rational vaccinology with spherical nucleic acids. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10473-10481.	3.3	82
309	Rapid research autopsy is a stealthy but growing contributor to cancer research. <i>Cancer</i> , 2019, 125, 2915-2919.	2.0	19
310	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	0.8	185

#	ARTICLE	IF	CITATIONS
311	Macroscale biomaterials strategies for local immunomodulation. <i>Nature Reviews Materials</i> , 2019, 4, 379-397.	23.8	172
312	Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity. <i>Frontiers in Immunology</i> , 2019, 10, 999.	2.2	47
313	Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 509-515.	1.4	16
314	Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells. <i>Molecular Therapy</i> , 2019, 27, 900-901.	3.7	3
315	Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors. <i>JAMA Network Open</i> , 2019, 2, e193433.	2.8	8
316	Precision oncology of lung cancer: genetic and genomic differences in Chinese population. <i>Npj Precision Oncology</i> , 2019, 3, 14.	2.3	31
317	Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know. <i>American Journal of Neuroradiology</i> , 2019, 40, 766-768.	1.2	12
318	CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy. <i>Nature</i> , 2019, 569, 270-274.	13.7	1,528
319	Proximity-induced hybridization chain assembly with small-molecule linked DNA for single-step amplified detection of antibodies. <i>Chemical Communications</i> , 2019, 55, 4387-4390.	2.2	16
320	Functional genomics in the era of cancer immunotherapy: challenges and clinical implications. <i>Briefings in Functional Genomics</i> , 2019, 18, 83-85.	1.3	0
321	An Optogenetic Controllable T Cell System for Hepatocellular Carcinoma Immunotherapy. <i>Theranostics</i> , 2019, 9, 1837-1850.	4.6	33
322	Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. <i>EBioMedicine</i> , 2019, 42, 363-374.	2.7	257
323	Immunotherapy in colorectal cancer: rationale, challenges and potential. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 361-375.	8.2	1,039
324	Design, synthesis and biological evaluation of 2,5-dimethylfuran-3-carboxylic acid derivatives as potential IDO1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1605-1618.	1.4	13
325	Heteroleptic Ruthenium Polypyridyl Complex Had Differential Effects on the Production of Pro-inflammatory Cytokines TNF $\alpha$ , IL1 $\beta$ , and IL6 by the Mammalian Macrophages In Vitro. <i>Inflammation</i> , 2019, 42, 1383-1388.	1.7	10
326	Ongoing and future directions in the management of metastatic colorectal cancer: Update on clinical trials. <i>Journal of Surgical Oncology</i> , 2019, 119, 642-652.	0.8	28
327	Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 236.	1.3	11
328	Enhanced Antitumor Immune Response in 2 $\alpha$ -5 $\alpha$ Oligoadenylate Synthetase-Like 1- (OASL1-) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy. <i>Journal of Immunology Research</i> , 2019, 2019, 1-14.	0.9	3

#	ARTICLE	IF	CITATIONS
329	Precision immunomodulation with synthetic nucleic acid technologies. <i>Nature Reviews Materials</i> , 2019, 4, 451-458.	23.3	27
330	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. <i>Advanced Healthcare Materials</i> , 2019, 8, e1801320.	3.9	43
331	Emerging Nano- and Microapproaches for Cancer Immunotherapy. <i>Advanced Science</i> , 2019, 6, 1801847.	5.6	136
332	Neutrophils escort circulating tumour cells to enable cell cycle progression. <i>Nature</i> , 2019, 566, 553-557.	13.7	804
333	Photo-induced anti-inflammatory activities of chloro substituted subphthalocyanines on the mammalian macrophage in vitro. <i>Photodiagnosis and Photodynamic Therapy</i> , 2019, 25, 499-503.	1.3	15
334	Aluminum doped carbon nanodots as potent adjuvants on the mammalian macrophages. <i>Molecular Biology Reports</i> , 2019, 46, 2405-2415.	1.0	18
335	Selective inhibition of low-affinity memory CD8+ T cells by corticosteroids. <i>Journal of Experimental Medicine</i> , 2019, 216, 2701-2713.	4.2	82
336	Bisbenzoxazole derivatives had an antiinflammatory effect on in vitro stimulated macrophages. <i>Turkish Journal of Chemistry</i> , 2019, 43, 963-971.	0.5	4
337	Decellularized Lymph Node Scaffolding as a Carrier for Dendritic Cells to Induce Anti-Tumor Immunity. <i>Pharmaceutics</i> , 2019, 11, 553.	2.0	10
338	Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouse. <i>Biomedical Research</i> , 2019, 40, 243-250.	0.3	26
339	Inflammation induced by incomplete radiofrequency ablation accelerates tumor progression and hinders PD-1 immunotherapy. <i>Nature Communications</i> , 2019, 10, 5421.	5.8	151
340	Revisiting the Genomic and Transcriptomic Landscapes from Female Malignancies Could Provide Molecular Markers and Targets for Precision Medicine. <i>Archives of Medical Research</i> , 2019, 50, 428-436.	1.5	4
341	Mitochondria-Targeting Immunogenic Cell Death Inducer Improves the Adoptive T-Cell Therapy Against Solid Tumor. <i>Frontiers in Oncology</i> , 2019, 9, 1196.	1.3	39
342	Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency. <i>Future Medicinal Chemistry</i> , 2019, 11, 2131-2150.	1.1	19
343	Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 272-289.	0.6	2
344	Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 317-329.	0.6	7
345	Soluble plasma programmed death 1 (PD-1) and Tim-3 in primary HIV infection. <i>Aids</i> , 2019, 33, 1253-1256.	1.0	20
346	The Current Status of Immunotherapy in Thoracic Malignancies. , 2019, , 45-75.		0

#	ARTICLE	IF	CITATIONS
347	Nano-, micro-, and macroscale drug delivery systems for cancer immunotherapy. <i>Acta Biomaterialia</i> , 2019, 85, 1-26.	4.1	142
348	CD73 as a potential opportunity for cancer immunotherapy. <i>Expert Opinion on Therapeutic Targets</i> , 2019, 23, 127-142.	1.5	102
349	PD-L1 expression and association with malignant behavior in pheochromocytomas/paragangliomas. <i>Human Pathology</i> , 2019, 86, 155-162.	1.1	15
350	Improved Efficacy of Antibody Cancer Immunotherapeutics through Local and Sustained Delivery. <i>ChemBioChem</i> , 2019, 20, 747-753.	1.3	12
351	Cancer Diagnostics and Therapeutics. <i>Bioanalysis</i> , 2019, , 33-66.	0.1	0
352	Comparative and combined effectiveness of innovative therapies in cancer: a literature review. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 205-216.	0.6	3
353	Tumor-Targeted Chemoimmunotherapy with Immune-Checkpoint Blockade for Enhanced Anti-Melanoma Efficacy. <i>AAPS Journal</i> , 2019, 21, 18.	2.2	8
354	Immune Signaling in Carcinogenesis. , 2019, , 327-334.		1
355	Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms. <i>International Immunopharmacology</i> , 2019, 67, 160-175.	1.7	33
356	Engineering lymphocytes with RNAi. <i>Advanced Drug Delivery Reviews</i> , 2019, 141, 55-66.	6.6	21
357	Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2019, , 3-24.	0.0	0
358	DNA-Based Scaffolds for Sensing Applications. <i>Analytical Chemistry</i> , 2019, 91, 44-59.	3.2	80
359	Genomic and epigenomic perspectives of T-cell exhaustion in cancer. <i>Briefings in Functional Genomics</i> , 2019, 18, 113-118.	1.3	6
360	Decoding cancer cell death-driven immune cell recruitment: An in vivo method for site-of-vaccination analyses. <i>Methods in Enzymology</i> , 2020, 636, 185-207.	0.4	9
361	Association of autoimmunity and cancer: An emphasis on proteolytic enzymes. <i>Seminars in Cancer Biology</i> , 2020, 64, 19-28.	4.3	13
362	Benefit, burden, and impact for a cohort of post-approval cancer combination trials. <i>Clinical Trials</i> , 2020, 17, 18-29.	0.7	5
363	A systematic review on Piper longum L.: Bridging traditional knowledge and pharmacological evidence for future translational research. <i>Journal of Ethnopharmacology</i> , 2020, 247, 112255.	2.0	87
364	Advances in mathematical models of the active targeting of tumor cells by functional nanoparticles. <i>Computer Methods and Programs in Biomedicine</i> , 2020, 184, 105106.	2.6	14

#	ARTICLE	IF	CITATIONS
365	Spinal sarcomas and immunity: An undervalued relationship. <i>Seminars in Cancer Biology</i> , 2020, 64, 36-50.	4.3	2
366	Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN- $\gamma$ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy. <i>Cancer Biology and Therapy</i> , 2020, 21, 130-138.	1.5	6
367	Role of myeloid cells in the immunosuppressive microenvironment in gliomas. <i>Immunobiology</i> , 2020, 225, 151853.	0.8	50
368	CART manufacturing process and reasons for academy-pharma collaboration. <i>Immunology Letters</i> , 2020, 217, 39-48.	1.1	9
369	RNA Nanotechnology-Mediated Cancer Immunotherapy. <i>Theranostics</i> , 2020, 10, 281-299.	4.6	100
370	Multiplex immunohistochemistry/immunofluorescence is superior to tumor mutational burden and PD-L1 immunohistochemistry for predicting response to anti-PD-L1/PD-L1 immunotherapy. <i>Thoracic Cancer</i> , 2020, 11, 3-5.		1
371	Horses for courses: an approach to the qualification of clinical trial sites and investigators in ATMPs. <i>Drug Discovery Today</i> , 2020, 25, 265-268.	3.2	7
372	Differential Immunomodulatory Effect of Carbon Dots Influenced by the Type of Surface Passivation Agent. <i>Inflammation</i> , 2020, 43, 777-783.	1.7	14
373	Patterns of immune infiltration in lung adenocarcinoma revealed a prognosis-associated microRNA-mast cells network. <i>Human Cell</i> , 2020, 33, 205-219.	1.2	6
374	Adverse kidney effects of immunotherapies. , 2020, , 166-182.e3.		0
375	Novel Copper Bearing Schiff Bases with Photodynamic Anti-Inflammatory and Anti-Microbial Activities. <i>Applied Biochemistry and Biotechnology</i> , 2020, 191, 716-727.	1.4	10
376	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	1.2	31
377	Immunostimulatory Activities of Coliphages on In Vitro Activated Mammalian Macrophages. <i>Inflammation</i> , 2020, 43, 595-604.	1.7	9
378	Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1042-1048.	1.4	29
379	The microcosmos of intratumor heterogeneity: the space-time of cancer evolution. <i>Oncogene</i> , 2020, 39, 2031-2039.	2.6	48
380	Defining the right diluent for intravenous infusion of therapeutic antibodies. <i>MAbs</i> , 2020, 12, 1685814.	2.6	18
381	Analysis of cancer cell-intrinsic immune regulation in response to CD8 + T cell attack. <i>Methods in Enzymology</i> , 2020, 631, 443-466.	0.4	0
382	Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. <i>Clinical Cancer Research</i> , 2020, 26, 984-989.	3.2	100

#	ARTICLE	IF	CITATIONS
383	Cell Reprogramming for Immunotherapy. <i>Methods in Molecular Biology</i> , 2020, , .	0.4	2
384	m <sup>6</sup> A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy. <i>EMBO Journal</i> , 2020, 39, e104514.	3.5	229
385	Identification of the Prognostic Value of Immune-Related Genes in Esophageal Cancer. <i>Frontiers in Genetics</i> , 2020, 11, 989.	1.1	16
386	Nonpeptidic quinazolinone derivatives as dual nucleotide-binding oligomerization domain-like receptor 1/2 antagonists for adjuvant cancer chemotherapy. <i>European Journal of Medicinal Chemistry</i> , 2020, 207, 112723.	2.6	4
387	Antibody and antibody fragments for cancer immunotherapy. <i>Journal of Controlled Release</i> , 2020, 328, 395-406.	4.8	63
388	Overview of Current Progress in Immune Checkpoint Inhibitor Therapy for Advanced Hepatocellular Carcinoma. <i>Technology in Cancer Research and Treatment</i> , 2020, 19, 153303382094748.	0.8	3
389	Safety and Efficacy of an Immune Cell-Specific Chimeric Promoter in Regulating Anti-PD-1 Antibody Expression in CAR T Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 19, 14-23.	1.8	9
390	Investigating the Immunostimulatory and Immunomodulatory Effects of cis and trans Isomers of Ruthenium Polypyridyl Complexes on the Mammalian Macrophage-Like Cells. <i>ChemistrySelect</i> , 2020, 5, 11648-11653.	0.7	5
391	Digitally quantified CD8+ cells: the best candidate marker for an immune cell score in non-small cell lung cancer?. <i>Carcinogenesis</i> , 2020, 41, 1671-1681.	1.3	18
392	Analysis of the molecular nature associated with microsatellite status in colon cancer identifies clinical implications for immunotherapy. , 2020, 8, e001437.		57
393	Research progress of nanomaterial-mediated photodynamic therapy in tumor treatment. <i>Journal of Nanoparticle Research</i> , 2020, 22, 1.	0.8	6
394	Neuropilin-1 is a T cell memory checkpoint limiting long-term antitumor immunity. <i>Nature Immunology</i> , 2020, 21, 1010-1021.	7.0	85
395	Sex and Gender Disparities in Melanoma. <i>Cancers</i> , 2020, 12, 1819.	1.7	69
396	Nanoscale covalent organic frameworks as theranostic platforms for oncotherapy: synthesis, functionalization, and applications. <i>Nanoscale Advances</i> , 2020, 2, 3656-3733.	2.2	100
397	TraPS-Varl: Identifying genetic variants altering phosphotyrosine based signalling motifs. <i>Scientific Reports</i> , 2020, 10, 8453.	1.6	1
399	Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy. <i>Medicine in Drug Discovery</i> , 2020, 8, 100073.	2.3	10
400	Long-term outcome after combined kyphoplasty and intraoperative radiotherapy (Kypho-IORT) for vertebral tumors. <i>Radiation Oncology</i> , 2020, 15, 263.	1.2	9
401	<p></p>Adverse Effects of Immune-Checkpoint Inhibitors in Hepatocellular Carcinoma</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11725-11740.	1.0	25

#	ARTICLE	IF	CITATIONS
402	Enhancing Combined Immunotherapy and Radiotherapy through Nanomedicine. <i>Bioconjugate Chemistry</i> , 2020, 31, 2668-2678.	1.8	13
403	Exploiting Ca <sup>2+</sup> signaling in T cells to advance cancer immunotherapy. <i>Seminars in Immunology</i> , 2020, 49, 101434.	2.7	7
404	Vaccination in Atherosclerosis. <i>Cells</i> , 2020, 9, 2560.	1.8	24
405	Improving antitumor efficacy via combinatorial regimens of oncolytic virotherapy. <i>Molecular Cancer</i> , 2020, 19, 158.	7.9	53
406	<p>Role of GLUT-1 in the Upregulation of PD-L1 Expression After Radiotherapy and Association of PD-L1 with Favourable Overall Survival in Hypopharyngeal Cancer</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 11221-11235.	1.0	11
407	Ex vivo Live Cell Imaging of Nanoparticle-Cell Interactions in the Mouse Lung. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 588922.	2.0	5
408	In vivo tracking of single cells with PET. <i>Nature Biomedical Engineering</i> , 2020, 4, 765-766.	11.6	6
409	Inhibition of glucuronomannan hexamer on the proliferation of lung cancer through binding with immunoglobulin G. <i>Carbohydrate Polymers</i> , 2020, 248, 116785.	5.1	9
410	Nanomaterials as Smart Immunomodulator Delivery System for Enhanced Cancer Therapy. <i>ACS Biomaterials Science and Engineering</i> , 2020, 6, 4774-4798.	2.6	23
411	Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumor. <i>IOP Conference Series: Materials Science and Engineering</i> , 2020, 768, 052051.	0.3	1
412	Nanotherapeutics for Antimetastatic Treatment. <i>Trends in Cancer</i> , 2020, 6, 645-659.	3.8	49
413	Generating a Novel Bispecific Nanobody to Enhance Antitumor Activity. <i>Pharmaceutical Fronts</i> , 2020, 02, e100-e108.	0.4	2
414	An overview on precision therapy in bladder cancer. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 347-361.	0.4	0
415	Novel Therapeutic Approaches of Ion Channels and Transporters in Cancer. <i>Reviews of Physiology, Biochemistry and Pharmacology</i> , 2020, , 1.	0.9	6
416	Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence. <i>Advanced Science</i> , 2020, 7, 2001447.	5.6	30
417	Immunotherapy in Hematologic Malignancies: Emerging Therapies and Novel Approaches. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8000.	1.8	25
418	Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture. <i>Frontiers in Immunology</i> , 2020, 11, 565631.	2.2	24
420	Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy. <i>Biomaterials</i> , 2020, 263, 120380.	5.7	11



#	ARTICLE	IF	CITATIONS
421	Oncolytic Immunotherapy: Canâ€™t Start a Fire Without a Spark. Cytokine and Growth Factor Reviews, 2020, 56, 94-101.	3.2	9
422	Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation. Seminars in Cancer Biology, 2022, 80, 340-355.	4.3	51
423	Immunostimulatory biomaterials to boost tumor immunogenicity. Biomaterials Science, 2020, 8, 5516-5537.	2.6	11
424	Cardioâ€œncology care in the era of the coronavirus disease 2019 (COVIDâ€œ19) pandemic: An International Cardioâ€œncology Society (ICOS) statement. Ca-A Cancer Journal for Clinicians, 2020, 70, 480-504.	157.7	29
425	Enhancing Delivery of Smallâ€œMoleculeâ€œand Cellâ€œBased Therapies for Ovarian Cancer Using Advanced Delivery Strategies. Advanced Therapeutics, 2020, 3, 2000144.	1.6	1
426	Chimeric antigen receptor T-cell lymphoma immunotherapy: the next questions. Current Opinion in Oncology, 2020, 32, 434-441.	1.1	3
427	Lipid Metabolism and Cancer Immunotherapy: Immunosuppressive Myeloid Cells at the Crossroad. International Journal of Molecular Sciences, 2020, 21, 5845.	1.8	51
428	Tetramer Immunization and Selection Followed by CELLISA Screening to Generate Monoclonal Antibodies against the Mouse Cytomegalovirus m12 Immuno-evasin. Journal of Immunology, 2020, 205, 1709-1717.	0.4	3
429	Pre-sensitization of Malignant B Cells Through Venetoclax Significantly Improves the Cytotoxic Efficacy of CD19.CAR-T Cells. Frontiers in Immunology, 2020, 11, 608167.	2.2	23
430	ExoHCR: a sensitive assay to profile PD-L1 level on tumor exosomes for immunotherapeutic prognosis. Biophysics Reports, 2020, 6, 290-298.	0.2	2
431	Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. Pharmaceutics, 2020, 12, 1054.	2.0	77
432	Thermosensitive Polymer Dot Nanocomposites for Trimodal Computed Tomography/Photoacoustic/Fluorescence Imaging-Guided Synergistic Chemo-Photothermal Therapy. ACS Applied Materials & Interfaces, 2020, 12, 51174-51184.	4.0	23
433	Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer. BMC Cancer, 2020, 20, 445.	1.1	11
434	Aptamer-T Cell Targeted Therapy for Tumor Treatment Using Sugar Metabolism and Click Chemistry. ACS Chemical Biology, 2020, 15, 1554-1565.	1.6	28
435	Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges. Journal of Nanobiotechnology, 2020, 18, 75.	4.2	61
436	Adverse events of targeted anticancer therapies: What radiologists need to know. Radiologia, 2020, 62, 229-242.	0.3	0
437	Characterization of tumour-infiltrating lymphocytes in a tumour rejection cynomolgus macaque model. Scientific Reports, 2020, 10, 8414.	1.6	5
438	Simulation study of the effects of interstitial fluid pressure and blood flow velocity on transvascular transport of nanoparticles in tumor microenvironment. Computer Methods and Programs in Biomedicine, 2020, 193, 105493.	2.6	19

#	ARTICLE	IF	CITATIONS
439	Current Strategies and Novel Therapeutic Approaches for Metastatic Urothelial Carcinoma. <i>Cancers</i> , 2020, 12, 1449.	1.7	72
440	Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 112.	3.5	158
441	Surface-Enhanced Raman Spectroscopy for Cancer Immunotherapy Applications: Opportunities, Challenges, and Current Progress in Nanomaterial Strategies. <i>Nanomaterials</i> , 2020, 10, 1145.	1.9	21
442	An iRGD peptide fused superantigen mutant induced tumor-targeting and T lymphocyte infiltrating in cancer immunotherapy. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119498.	2.6	11
443	Regulation of Cancer Immune Checkpoints. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	7
444	Immunotherapy, Inflammation and Colorectal Cancer. <i>Cells</i> , 2020, 9, 618.	1.8	167
445	Polymeric Nonviral Gene Delivery Systems for Cancer Immunotherapy. <i>Advanced Therapeutics</i> , 2020, 3, 1900213.	1.6	30
446	Development of oncolytic virotherapy: from genetic modification to combination therapy. <i>Frontiers of Medicine</i> , 2020, 14, 160-184.	1.5	40
447	Progress in transdermal drug delivery systems for cancer therapy. <i>Nano Research</i> , 2020, 13, 1810-1824.	5.8	54
448	ImmunoPET: Concept, Design, and Applications. <i>Chemical Reviews</i> , 2020, 120, 3787-3851.	23.0	263
449	Irradiated tumor cell-derived microparticles mediate tumor eradication via cell killing and immune reprogramming. <i>Science Advances</i> , 2020, 6, eaay9789.	4.7	139
450	The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1423-1436.	2.0	36
451	Ten things the hematologist wants you to know about CAR-T cells. <i>Intensive Care Medicine</i> , 2020, 46, 1243-1245.	3.9	5
452	The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma. <i>BioDrugs</i> , 2020, 34, 349-362.	2.2	33
453	Inhibition of Tryptophan-Dioxygenase Activity Increases the Antitumor Efficacy of Immune Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2020, 8, 32-45.	1.6	48
454	Intratumoral Delivery of a PD-1-Blocking scFv Encoded in Oncolytic HSV-1 Promotes Antitumor Immunity and Synergizes with TIGIT Blockade. <i>Cancer Immunology Research</i> , 2020, 8, 632-647.	1.6	42
455	Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer. <i>International Journal of Cancer</i> , 2020, 147, 1963-1969.	2.3	28
456	Hyperacacis in children: a scoping review. <i>BMC Pediatrics</i> , 2020, 20, 319.	0.7	14

#	ARTICLE	IF	CITATIONS
458	The Interplay between Antioxidants and the Immune System: A Promising Field, Still Looking for Answers. <i>Nutrients</i> , 2020, 12, 1550.	1.7	2
459	Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy. <i>Science Advances</i> , 2020, 6, eaba8564.	4.7	66
460	Competition NMR for Detection of Hit/Lead Inhibitors of Protein-Protein Interactions. <i>Molecules</i> , 2020, 25, 3017.	1.7	11
461	Immunological microenvironment gene expression in patients with diffuse large B cell non Hodgkin lymphoma. <i>Biochemistry and Biophysics Reports</i> , 2020, 21, 100731.	0.7	6
462	The Impact of Focused Ultrasound in Two Tumor Models: Temporal Alterations in the Natural History on Tumor Microenvironment and Immune Cell Response. <i>Cancers</i> , 2020, 12, 350.	1.7	11
463	Cell Tracking in Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2020, 7, 34.	1.2	52
464	Kinetics of pH-dependent interactions between PD-1 and PD-L1 immune checkpoint proteins from molecular dynamics. <i>Proteins: Structure, Function and Bioinformatics</i> , 2020, 88, 1162-1168.	1.5	4
465	Tumor-targeting oncolytic virus elicits potent immunotherapeutic vaccine responses to tumor antigens. <i>Oncolimmunology</i> , 2020, 9, 1726168.	2.1	9
466	Stimuli-responsive nanoparticle-assisted immunotherapy: a new weapon against solid tumours. <i>Journal of Materials Chemistry B</i> , 2020, 8, 1823-1840.	2.9	32
467	Ruthenium Bipyridyl Dithiocyanate Complex Exerted Adjuvant Activity on the Activated Mammalian Macrophages in vitro. <i>Inflammation</i> , 2020, 43, 1120-1126.	1.7	2
468	Monitoring CD8a+ T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [64Cu]NOTA-CD8a PET Imaging. <i>Molecular Imaging and Biology</i> , 2020, 22, 1021-1030.	1.3	16
469	Immunotherapy with immune checkpoint inhibitors in colorectal cancer: what is the future beyond deficient mismatch-repair tumours?. <i>Gastroenterology Report</i> , 2020, 8, 11-24.	0.6	68
470	Chlorin e6 and polydopamine modified gold nanoflowers for combined photothermal and photodynamic therapy. <i>Journal of Materials Chemistry B</i> , 2020, 8, 2128-2138.	2.9	37
471	New approaches to the study of immune responses in humans. <i>Human Genetics</i> , 2020, 139, 795-799.	1.8	5
472	Targeted Nano-Drug Delivery of Colchicine against Colon Cancer Cells by Means of Mesoporous Silica Nanoparticles. <i>Cancers</i> , 2020, 12, 144.	1.7	60
473	Cancer Nano-Immunotherapy from the Injection to the Target: The Role of Protein Corona. <i>International Journal of Molecular Sciences</i> , 2020, 21, 519.	1.8	19
474	Patient-derived organoid analysis of drug resistance in precision medicine: is there a value?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 1-5.	0.4	26
475	The Design of Poly(lactide-co-glycolide) Nanocarriers for Medical Applications. <i>Frontiers in Bioengineering and Biotechnology</i> , 2020, 8, 48.	2.0	124

#	ARTICLE	IF	CITATIONS
476	Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists. <i>Cancers</i> , 2020, 12, 169.	1.7	5
477	Cellular backpacks for macrophage immunotherapy. <i>Science Advances</i> , 2020, 6, eaaz6579.	4.7	224
478	Reprogramming Tumor Microenvironment with Photothermal Therapy. <i>Bioconjugate Chemistry</i> , 2020, 31, 1268-1278.	1.8	66
479	Targeted delivery of a short antimicrobial peptide against CD44-overexpressing tumor cells using hyaluronic acid-coated chitosan nanoparticles: An in vitro study. <i>Journal of Nanoparticle Research</i> , 2020, 22, 1.	0.8	20
480	Inflammatory Responses during Tumour Initiation: From Zebrafish Transgenic Models of Cancer to Evidence from Mouse and Man. <i>Cells</i> , 2020, 9, 1018.	1.8	15
481	Tuning up Transcription Factors for Therapy. <i>Molecules</i> , 2020, 25, 1902.	1.7	11
482	Hepatocellular carcinoma, novel therapies on the horizon. <i>Chinese Clinical Oncology</i> , 2021, 10, 12-12.	0.4	12
483	Recent advances in nanoscale materials for antibody-based cancer theranostics. <i>Biosensors and Bioelectronics</i> , 2021, 173, 112787.	5.3	12
484	Biomarkers for predicting the outcome of various cancer immunotherapies. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103161.	2.0	10
485	Lysosomal Acid Lipase Deficiency Controls T- and B-Regulatory Cell Homeostasis in the Lymph Nodes of Mice with Human Cancer Xenotransplants. <i>American Journal of Pathology</i> , 2021, 191, 353-367.	1.9	12
486	Expression pattern, regulation, and clinical significance of TOX in breast cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 349-363.	2.0	13
487	Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma. <i>Annals of Pharmacotherapy</i> , 2021, 55, 390-405.	0.9	13
488	<sc>TSNP</sc>: A <sc>twoâ€stage</sc> nonparametric phase I<sc>II</sc> clinical trial design for immunotherapy. <i>Pharmaceutical Statistics</i> , 2021, 20, 282-296.	0.7	5
489	Immunotherapeutic strategies for the treatment of ovarian cancer: current status and future direction. <i>Journal of Industrial and Engineering Chemistry</i> , 2021, 94, 62-77.	2.9	11
490	The Role of <sup>89</sup>Zr-Immuno-PET in Navigating and Derisking the Development of Biopharmaceuticals. <i>Journal of Nuclear Medicine</i> , 2021, 62, 438-445.	2.8	39
491	Near-infrared-responsive functional nanomaterials: the first domino of combined tumor therapy. <i>Nano Today</i> , 2021, 36, 100963.	6.2	30
492	Feasibility study of <sup>68</sup> Ga-labeled CARÂT cells for in vivo tracking using micro-positron emission tomography imaging. <i>Acta Pharmacologica Sinica</i> , 2021, 42, 824-831.	2.8	18
493	Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer. <i>Seminars in Cancer Biology</i> , 2021, 68, 84-91.	4.3	21

#	ARTICLE	IF	CITATIONS
494	Intelligent stimuli-responsive nano immunomodulators for cancer immunotherapy. <i>Chemical Science</i> , 2021, 12, 3130-3145.	3.7	26
495	Immuno-modulating Mediators of Colon Cancer as Immuno-therapeutic: Mechanism and Potential. , 2021, , 271-308.		0
496	HPMA-Based Copolymers Carrying STAT3 Inhibitor Cucurbitacin-D as Stimulus-Sensitive Nanomedicines for Oncotherapy. <i>Pharmaceutics</i> , 2021, 13, 179.	2.0	4
497	Human gut microbial communities dictate efficacy of anti-PD-1 therapy in a humanized microbiome mouse model of glioma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab023.	0.4	10
498	Chimeric Antigen Receptor (CAR) T Cell Therapy for Digestive Tumor. <i>E3S Web of Conferences</i> , 2021, 271, 03065.	0.2	0
499	Multifunctional theranostic nanomedicine for photoacoustic imaging-guided combination tumor treatment. , 2021, , 67-90.		1
500	Immunomodulatory potential of chitosan-based materials for cancer therapy: a systematic review of <i>in vitro</i> , <i>in vivo</i> and clinical studies. <i>Biomaterials Science</i> , 2021, 9, 3209-3227.	2.6	22
501	<i>In vivo</i> trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. <i>Oncolmmunology</i> , 2021, 10, 1966970.	2.1	2
502	MicroRNAs in head and neck squamous cell carcinoma: a possible challenge as biomarkers, determinants for the choice of therapy and targets for personalized molecular therapies. <i>Translational Cancer Research</i> , 2021, 10, 3090-3110.	0.4	15
503	Next Generation Therapeutic Strategies: Evolving cancer immunotherapy through agents that Engage , Expand and Enable the anti-tumor immune response. <i>Immunomedicine</i> , 2021, 1, e1020.	0.7	6
504	Effects of interleukin-2 concentration and administration method on proliferation and function of cytokine-induced killer cells. <i>Translational Cancer Research</i> , 2021, 10, 3930-3938.	0.4	1
505	A summary of current NKG2D-based CAR clinical trials. <i>Immunotherapy Advances</i> , 2021, 1, Itab018.	1.2	28
506	Radionuclide-based molecular imaging allows CAR-T cellular visualization and therapeutic monitoring. <i>Theranostics</i> , 2021, 11, 6800-6817.	4.6	21
507	Gut Microbiome and Liver Cancer. <i>Physiology in Health and Disease</i> , 2021, , 199-255.	0.2	0
508	Are radiologists ready to evaluate true response to immunotherapy?. <i>Insights Into Imaging</i> , 2021, 12, 29.	1.6	5
510	Dissecting the impact of target-binding kinetics of protein binders on tumor localization. <i>IScience</i> , 2021, 24, 102104.	1.9	3
511	Novel Complex of PD-L1 Aptamer and Holliday Junction Enhances Antitumor Efficacy in Vivo. <i>Molecules</i> , 2021, 26, 1067.	1.7	17
512	Cell-derived vesicles for delivery of cancer immunotherapy. <i>Exploration of Medicine</i> , 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
513	Cell-derived vesicles for delivery of cancer immunotherapy. <i>Exploration of Medicine</i> , 0, , .	1.5	1
514	Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy. <i>Nature Communications</i> , 2021, 12, 1359.	5.8	64
515	Nanomedicine-driven molecular targeting, drug delivery, and therapeutic approaches to cancer chemoresistance. <i>Drug Discovery Today</i> , 2021, 26, 724-739.	3.2	25
516	CRISPR/Cas: Advances, Limitations, and Applications for Precision Cancer Research. <i>Frontiers in Medicine</i> , 2021, 8, 649896.	1.2	48
517	Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 535.	0.8	6
518	Application of immune checkpoint targets in the anti-tumor novel drugs and traditional Chinese medicine development. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 2957-2972.	5.7	34
519	Nanoengineered CAR <sup>T</sup> Biohybrids for Solid Tumor Immunotherapy with Microenvironment Photothermal <sup>T</sup> Remodeling Strategy. <i>Small</i> , 2021, 17, e2007494.	5.2	44
520	Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022, 22, 433-468.	0.9	7
521	Point-source burst of coordination polymer nanoparticles for tri-modality cancer therapy. <i>Biomaterials</i> , 2021, 270, 120690.	5.7	21
522	The immune suppressive microenvironment affects efficacy of radio <sup>T</sup> immunotherapy in brain metastasis. <i>EMBO Molecular Medicine</i> , 2021, 13, e13412.	3.3	26
523	Promises and challenges of adoptive T-cell therapies for solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 1759-1776.	2.9	113
524	Cell <sup>T</sup> Based Delivery Systems: Emerging Carriers for Immunotherapy. <i>Advanced Functional Materials</i> , 2021, 31, 2100088.	7.8	60
525	Immune Checkpoint Inhibitor <sup>T</sup> Based Strategies for Synergistic Cancer Therapy. <i>Advanced Healthcare Materials</i> , 2021, 10, e2002104.	3.9	47
526	Development of a Prognostic Model for Ovarian Cancer Patients Based on Novel Immune Microenvironment Related Genes. <i>Frontiers in Oncology</i> , 2021, 11, 647273.	1.3	9
527	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	39
529	Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non <sup>T</sup> Small-Cell Lung Cancer After Previous Systemic Treatment Failure <sup>T</sup> A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 628124.	1.3	39
530	Modeling CAR T-Cell Therapy with Patient Preconditioning. <i>Bulletin of Mathematical Biology</i> , 2021, 83, 42.	0.9	22
531	The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 556-568.	2.0	28

#	ARTICLE	IF	CITATIONS
532	Imaging Biomarkers to Predict and Evaluate the Effectiveness of Immunotherapy in Advanced Non-Small-Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 657615.	1.3	29
533	Nanovaccine-Based Strategies to Overcome Challenges in the Whole Vaccination Cascade for Tumor Immunotherapy. <i>Small</i> , 2021, 17, e2006000.	5.2	53
534	Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials. , 2021, 9, e002114.		10
535	MiRNA-138-5p: A strong tumor suppressor targeting PD-L1 inhibits proliferation and motility of breast cancer cells and induces apoptosis. <i>European Journal of Pharmacology</i> , 2021, 896, 173933.	1.7	21
536	Vector engineering, strategies and targets in cancer gene therapy. <i>Cancer Gene Therapy</i> , 2022, 29, 402-417.	2.2	18
537	Identification of Biomarkers Related to Immune Cell Infiltration in Hepatocellular Carcinoma Using Gene Co-Expression Network. <i>Pathology and Oncology Research</i> , 2021, 27, 601693.	0.9	2
538	The Design of Gold Decorated Iron Borates (Fe <sub>3</sub> BO <sub>6</sub> and FeBO <sub>3</sub> ) for Photothermal Therapy and Boron Carriers. <i>European Journal of Inorganic Chemistry</i> , 2021, 2021, 1985-1992.	1.0	3
539	The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 654877.	2.2	19
540	The C-Terminal Domain of Nefmut Is Dispensable for the CD8+ T Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles. <i>Vaccines</i> , 2021, 9, 373.	2.1	4
541	Oncofertility Information Available for Recently Approved Novel Non Cytotoxic and Immunotherapy Oncology Drugs. <i>Clinical Pharmacology and Therapeutics</i> , 2022, 111, 382-390.	2.3	7
542	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. <i>Cancers</i> , 2021, 13, 2225.	1.7	21
543	A Series of 2-((1-Phenyl-1H-imidazol-5-yl)methyl)-1H-indoles as Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors. <i>ChemMedChem</i> , 2021, 16, 2195-2205.	1.6	9
544	Inhibitors of immuno-oncology target HPK1 – a patent review (2016 to 2020). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 893-910.	2.4	13
545	Nanoparticle-enabled innate immune stimulation activates endogenous tumor-infiltrating T cells with broad antigen specificities. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	14
546	Implications of Enhancer Transcription and eRNAs in Cancer. <i>Cancer Research</i> , 2021, 81, 4174-4182.	0.4	38
547	TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy. <i>Diagnostics</i> , 2021, 11, 844.	1.3	2
548	Prodrugs and prodrug-activated systems in gene therapy. <i>Molecular Therapy</i> , 2021, 29, 1716-1728.	3.7	26
549	Translational Applications of Hydrogels. <i>Chemical Reviews</i> , 2021, 121, 11385-11457.	23.0	438

#	ARTICLE	IF	CITATIONS
550	Ionic Liquid-Enabled Topical Delivery of Immunomodulators. ACS Biomaterials Science and Engineering, 2021, 7, 2783-2790.	2.6	12
551	Glycosylation of Immune Receptors in Cancer. Cells, 2021, 10, 1100.	1.8	32
552	Intratumoral (Poly-ICLC) Therapy for Dogs with Advanced Cancers: First Report on Clinical Effectiveness, Quality of Life, and Adverse Events. Cancers, 2021, 13, 2237.	1.7	1
553	Correlation Between Contrast-Enhanced Ultrasound and Immune Response of Distant Hepatocellular Carcinoma After Radiofrequency Ablation in a Murine Model. Journal of Ultrasound in Medicine, 2022, 41, 713-723.	0.8	4
554	Multi-detector computed tomography (MDCT)-based severity score as a prognostic tool in patients with suspected immune checkpoint inhibitor therapy associated colitis. European Radiology, 2021, 31, 8868-8878.	2.3	2
555	Evaluation of the In Vivo Acute Toxicity and In Vitro Hemolytic and Immunomodulatory Activities of the Moringa oleifera Flower Trypsin Inhibitor (MoFTI). Protein and Peptide Letters, 2021, 28, 665-674.	0.4	5
556	Application and research progress of <i>in vitro</i> liver cancer cell culture models. World Chinese Journal of Digestology, 2021, 29, 563-570.	0.0	1
557	“Mind the GAP” RGS1 hinders antitumor lymphocytes. Nature Immunology, 2021, 22, 802-804.	7.0	5
558	Emerging nanomaterials for cancer immunotherapy. Exploration of Medicine, 2021, 2, 208-231.	1.5	1
559	Multiplexed digital spatial profiling of invasive breast tumors from Black and White women. Molecular Oncology, 2022, 16, 54-68.	2.1	12
560	Effects of a Unique Combination of the Whole-Body Low Dose Radiotherapy with Inactivation of Two Immune Checkpoints and/or a Heat Shock Protein on the Transplantable Lung Cancer in Mice. International Journal of Molecular Sciences, 2021, 22, 6309.	1.8	8
561	PD-1 derived CA-170 is an oral immune checkpoint inhibitor that exhibits preclinical anti-tumor efficacy. Communications Biology, 2021, 4, 699.	2.0	79
562	In vitro and in vivo degradation of programmed cell death ligand 1 (PD-L1) by a proteolysis targeting chimera (PROTAC). Bioorganic Chemistry, 2021, 111, 104833.	2.0	37
563	Immunotherapy in endometrial cancer: rationale, practice and perspectives. Biomarker Research, 2021, 9, 49.	2.8	53
564	Oxygen-Generating Cryogels Restore T Cell Mediated Cytotoxicity in Hypoxic Tumors. Advanced Functional Materials, 2021, 31, 2102234.	7.8	17
566	An MRI-trackable therapeutic nanovaccine preventing cancer liver metastasis. Biomaterials, 2021, 274, 120893.	5.7	24
567	Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein-Protein Interaction. Journal of Medicinal Chemistry, 2021, 64, 11614-11636.	2.9	42
568	RAAS: A Convergent Player in Ischemic Heart Failure and Cancer. International Journal of Molecular Sciences, 2021, 22, 7106.	1.8	7



#	ARTICLE	IF	CITATIONS
569	Consensus of Minimally Invasive and Multidisciplinary Comprehensive Treatment for Hepatocellular Carcinoma – 2020 Guangzhou Recommendations. <i>Frontiers in Oncology</i> , 2021, 11, 621834.	1.3	4
570	IDO Inhibition Facilitates Antitumor Immunity of V $\beta$ 39V $\alpha$ 2 T Cells in Triple-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 679517.	1.3	15
571	Lipid Nanoparticle Spherical Nucleic Acids for Intracellular DNA and RNA Delivery. <i>Nano Letters</i> , 2021, 21, 6584-6591.	4.5	50
572	Prediction of chemoresistance trait of cancer cell lines using machine learning algorithms and systems biology analysis. <i>Journal of Big Data</i> , 2021, 8, .	6.9	4
573	The Next-Generation of Combination Cancer Immunotherapy: Epigenetic Immunomodulators Transmogrify Immune Training to Enhance Immunotherapy. <i>Cancers</i> , 2021, 13, 3596.	1.7	12
574	PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+V $\alpha$ 3 Treg polarization. <i>JCI Insight</i> , 2021, 6, .	2.3	26
575	Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study. <i>Frontiers in Pharmacology</i> , 2021, 12, 670900.	1.6	9
576	Laser/GSH-Activatable Oxaliplatin/Phthalocyanine-Based Coordination Polymer Nanoparticles Combining Chemophotodynamic Therapy to Improve Cancer Immunotherapy. <i>ACS Applied Materials &amp; Interfaces</i> , 2021, 13, 39934-39948.	4.0	31
577	Safety and feasibility of an in situ vaccination and immunomodulatory targeted radionuclide combination immuno-radiotherapy approach in a comparative (companion dog) setting. <i>PLoS ONE</i> , 2021, 16, e0255798.	1.1	12
578	Adverse Effects and Safety of Etoposide Pegol, a Novel Topoisomerase Inhibitor, in Cancer Treatment: A Systematic Review. <i>Current Cancer Therapy Reviews</i> , 2021, 17, 234-243.	0.2	0
579	Ansamitocin P3-Loaded Gold-NanoCage Conjugated with Immune Checkpoint Inhibitor to Enhance Photo-Chemo-Thermal Maturation of Dendritic Cells for Hepatocellular Carcinoma. <i>Polymers</i> , 2021, 13, 2726.	2.0	6
580	Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy. <i>Advanced Materials</i> , 2021, 33, e2103497.	11.1	73
581	Advances in culture methods for acute myeloid leukemia research. <i>Oncoscience</i> , 2021, 8, 82-90.	0.9	2
582	Potential role of melatonin in prevention and treatment of leukaemia. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2021, 42, 445-461.	0.3	2
583	Nanotechnology-based immunotherapies to combat cancer metastasis. <i>Molecular Biology Reports</i> , 2021, 48, 6563-6580.	1.0	8
584	Identification of active small-molecule modulators targeting the novel immune checkpoint VISTA. <i>BMC Immunology</i> , 2021, 22, 55.	0.9	11
585	The Challenge of ICI's Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?. <i>Frontiers in Immunology</i> , 2021, 12, 704942.	2.2	4
586	Responsive Dual-Targeting Exosome as a Drug Carrier for Combination Cancer Immunotherapy. <i>Research</i> , 2021, 2021, 9862876.	2.8	17

#	ARTICLE	IF	CITATIONS
587	Breast cancer immunotherapy: Current and novel approaches. <i>International Immunopharmacology</i> , 2021, 98, 107886.	1.7	42
588	Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach. , 2022, 231, 107986.		30
589	Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. , 2021, 9, e002627.		15
590	Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. <i>Annals of Lymphoma</i> , 2021, 5, 23-23.	4.5	3
591	Combining repurposed drugs to treat colorectal cancer. <i>Drug Discovery Today</i> , 2022, 27, 165-184.	3.2	10
592	Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 662-676.	3.2	38
593	Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin). <i>JCI Insight</i> , 2021, 6, .	2.3	7
594	Adoptive immunotherapy with transient anti-CD4 treatment enhances anti-tumor response by increasing IL-18R $\alpha$ hi CD8+ T cells. <i>Nature Communications</i> , 2021, 12, 5314.	5.8	12
595	Immunotherapy in hematological malignancies: recent advances and open questions. <i>Immunotherapy</i> , 2021, 13, 1215-1229.	1.0	11
596	Eradicating biofilm infections: an update on current and prospective approaches. <i>Current Opinion in Microbiology</i> , 2021, 63, 117-125.	2.3	34
597	Trans-palladium complexes with 1-adamantanamine and various halide ions: Synthesis, characterization, DNA and protein binding and in vitro cytotoxicity. <i>Polyhedron</i> , 2021, 209, 115458.	1.0	0
598	Metabolic reprogramming and immunity in cancer. , 2022, , 137-196.		1
599	Role of microbiome in cancer immunotherapy. , 2022, , 321-352.		1
600	CRISPR/Cas9-mediated knockout of clinically relevant alloantigenes in human primary T cells. <i>BMC Biotechnology</i> , 2021, 21, 9.	1.7	17
601	Nanomaterials to target immunity. <i>Advances in Pharmacology</i> , 2021, 91, 293-335.	1.2	3
602	Immune Checkpoint Inhibitors as an Armor for Targeted Immunotherapy of Colorectal Cancer. , 2021, , 309-326.		0
603	Quantum binding energies of checkpoint CTLA-4 in complex with the immuno-oncological drug ipilimumab. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 15620-15627.	1.3	5
604	Discovery of Hydroxyamidine Derivatives as Highly Potent, Selective Indoleamine-2,3-dioxygenase 1 Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2021, 12, 195-201.	1.3	3

#	ARTICLE	IF	CITATIONS
605	Leveraging Immunotherapy with Nanomedicine. <i>Advanced Therapeutics</i> , 2020, 3, 2000134.	1.6	2
606	Clinical Trials with Cytokine-Induced Killer Cells and CAR-T Cell Transplantation for Non-small Cell Lung Cancer Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1292, 113-130.	0.8	5
607	An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions. <i>Methods in Molecular Biology</i> , 2020, 2097, 139-171.	0.4	2
608	Therapeutic Development of Immune Checkpoint Inhibitors. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1248, 619-649.	0.8	15
609	Immunotherapy for the Treatment of Acute Lymphoblastic Leukemia. <i>Current Oncology Reports</i> , 2020, 22, 11.	1.8	13
610	Efectos adversos de las terapias dirigidas contra el c�ncer: lo que el radi�logo debe saber. <i>Radiologia</i> , 2020, 62, 229-242.	0.3	2
613	Enhanced CAR�T cell activity against solid tumors by vaccine boosting through the chimeric receptor. <i>Science</i> , 2019, 365, 162-168.	6.0	282
614	Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. <i>Radiographics</i> , 2017, 37, 2132-2144.	1.4	87
615	Emerging strategies for combination checkpoint modulators in cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 3209-3218.	3.9	170
616	Driving an improved CAR for cancer immunotherapy. <i>Journal of Clinical Investigation</i> , 2016, 126, 2795-2798.	3.9	13
617	Safety and efficacy of axicabtagene ciloleucel in refractory large B-cell lymphomas. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072090289.	1.1	13
618	PD-1/PD-L1 antagonists in gastric cancer: Current studies and perspectives. <i>World Journal of Meta-analysis</i> , 2019, 7, 101-109.	0.1	7
619	Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function. <i>PLoS ONE</i> , 2020, 15, e0243145.	1.1	10
620	EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. <i>Aging</i> , 2019, 11, 11054-11072.	1.4	52
621	Prediction of hepatocellular carcinoma prognosis based on expression of an immune-related gene set. <i>Aging</i> , 2020, 12, 965-977.	1.4	38
622	Significant benefit of Nivolumab treating PD-L1 positive metastatic pulmonary carcinosarcoma: a case report and literature review. <i>Oncotarget</i> , 2017, 8, 96453-96459.	0.8	8
623	Cancer immunotherapy: Moving beyond checkpoint inhibition. <i>Oncotarget</i> , 2018, 9, 36545-36546.	0.8	3
624	Drug resistance and combating drug resistance in cancer. <i>Cancer Drug Resistance (Alhambra, Calif)</i> , 2019, 2, 141-160.	0.9	388

#	ARTICLE	IF	CITATIONS
625	3,3â€™-Diindolylmethane and its derivatives: nature-inspired strategies tackling drug resistant tumors by regulation of signal transduction, transcription factors and microRNAs. , 2020, 3, 867-878.		7
626	Perspectives in small cell lung cancer: is something moving?. Translational Lung Cancer Research, 2017, 6, S47-S50.	1.3	1
628	Toward Small-Molecule Inhibition of Proteinâ€™-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions. Current Topics in Medicinal Chemistry, 2018, 18, 674-699.	1.0	69
629	Chitosan in Biomedical Engineering: A Critical Review. Current Stem Cell Research and Therapy, 2019, 14, 93-116.	0.6	165
630	Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 768-776.	0.9	6
631	Trichostatin A Sensitizes Hepatocellular Carcinoma Cells to Enhanced NK Cell-mediated Killing by Regulating Immune-related Genes. Cancer Genomics and Proteomics, 2017, 14, 349-362.	1.0	22
632	Immunostimulatory and Immunomodulatory Effects of Nitzschia navis-varingica, Heterocapsa pygmaea and Chrysochromulina alifera Whole Cell Extracts on Mammalian Macrophage Cells. Natural and Engineering Sciences, 2019, 4, 237-246.	0.2	2
633	Immune Response Checkpoint Inhibitors: New Risks of a New Class of Antitumor Agents. Safety and Risk of Pharmacotherapy, 2020, 8, 9-22.	0.1	10
634	Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer. Frontiers in Cell and Developmental Biology, 2020, 8, 351.	1.8	45
635	Platforms Exploited for SARS-CoV-2 Vaccine Development. Vaccines, 2021, 9, 11.	2.1	17
636	Multiparametric analysis of colorectal cancer immune responses. World Journal of Gastroenterology, 2018, 24, 2995-3005.	1.4	16
637	Radiofrequency combined with immunomodulation for hepatocellular carcinoma: State of the art and innovations. World Journal of Gastroenterology, 2020, 26, 2040-2048.	1.4	13
638	Effective pressure and treatment duration of high hydrostatic pressure to prepare melanoma vaccines. Oncology Letters, 2020, 20, 1135-1142.	0.8	6
639	Ambiguous roles and potential therapeutic strategies of innate lymphoid cells in different types of tumor (Review). Oncology Letters, 2020, 20, 1513-1525.	0.8	7
640	Impact of inflammation and immunotherapy in renal cell carcinoma (Review). Oncology Letters, 2020, 20, 1-1.	0.8	19
641	Immunotherapy a New Hope for Cancer Treatment: A Review. Pakistan Journal of Biological Sciences, 2018, 21, 135-150.	0.2	21
642	Peptide-Binding Groove Contraction Linked to the Lack of T Cell Response: Using Complex Structure and Energy To Identify Neoantigens. ImmunoHorizons, 2018, 2, 216-225.	0.8	8
643	Tumour Regression via Integrative Regulation of Neurological, Inflammatory, and Hypoxic Tumour Microenvironment. Biomolecules and Therapeutics, 2020, 28, 119-130.	1.1	13

#	ARTICLE	IF	CITATIONS
644	Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients. Turkish Journal of Haematology, 2020, 37, 234-247.	0.2	10
645	Physical Disruption of Solid Tumors by Immunostimulatory Microrobots Enhances Antitumor Immunity. Advanced Materials, 2021, 33, e2103505.	11.1	38
646	Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy. Pharmaceutics, 2021, 13, 1670.	2.0	28
647	Applications of Magnetite Nanoparticles in Cancer Immunotherapies: Present Hallmarks and Future Perspectives. Frontiers in Immunology, 2021, 12, 701485.	2.2	3
648	Nanomedicine potentiates mild photothermal therapy for tumor ablation. Asian Journal of Pharmaceutical Sciences, 2021, 16, 738-761.	4.3	43
649	A hybrid bacterium with tumor-associated macrophage polarization for enhanced photothermal-immunotherapy. Acta Pharmaceutica Sinica B, 2022, 12, 2683-2694.	5.7	17
650	Speed and Location Both Matter: Antigen Stimulus Dynamics Controls CAR-T Cell Response. Frontiers in Immunology, 2021, 12, 748768.	2.2	4
652	The TNF- $\alpha$ /TNFR2 Pathway: Targeting a Brake to Release the Anti-tumor Immune Response. Frontiers in Cell and Developmental Biology, 2021, 9, 725473.	1.8	21
653	Combinational Immunotherapy of Gastric Cancer. , 2017, , 163-175.		0
654	REVIEW OF APPROACHES TO IMMUNOTHERAPY IN ONCOLOGY. IssledovaniÅ I Praktika V Medicine, 2017, 4, 51-65.	0.1	4
655	Immunotherapy in Multiple Myeloma: The Era of CAR T Cell Therapy. , 2018, 15, .		0
656	PROSTATE AND BREAST CANCER. The Professional Medical Journal, 2018, 25, 703-708.	0.0	0
657	Makrofajlar Åœzerinde Å°mmÅ¼nostimÅ¼latÅ¼r ve Adjuvan Etkisi Olan Rutenyum BazlÅ± IÅŸÅ±ÅŸa BaÅŸlÅ± MolekÅ¼l. Cumhuriyet Science Journal, 2018, 39, 991-998.	0.1	12
658	Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. , 2019, , 551-600.		0
659	Gene Modification and Immunological Analyses for the Development of Immunotherapy Utilizing T Cells Redirected with Antigen-Specific Receptors. Methods in Molecular Biology, 2019, 2048, 27-39.	0.4	0
660	Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry. Methods in Molecular Biology, 2020, 2108, 159-165.	0.4	2
663	Chimeric Antigen Receptor T-Cell Immunotherapy for Cancer. , 2020, , .		1
664	Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation. Scientific Reports, 2021, 11, 21072.	1.6	9

#	ARTICLE	IF	CITATIONS
665	Immunomodulatory Effects of Jacalin, a Dietary Plant Lectin on the Peripheral Blood Mononuclear Cells (PBMCs). <i>Applied Biochemistry and Biotechnology</i> , 2021, , 1.	1.4	2
666	Development of immune gene pair-based signature predictive of prognosis and immunotherapy in esophageal cancer. <i>Annals of Translational Medicine</i> , 2021, 9, 1591-1591.	0.7	4
668	Identification of Immune-Related Genes for Establishment of Prognostic Index in Hepatocellular Carcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 760079.	1.8	0
669	Pharmacokinetics, Pharmacodynamics, and Toxicology Aspects of Immunotherapeutics. , 2021, , 195-214.		0
670	Cancer Treatment Modalities Systemic and Locoregional Approaches: Challenges and Opportunities of Multidisciplinary Approaches. , 2021, , 17-37.		1
671	Tight Interplay Between Therapeutic Monoclonal Antibodies and the Tumour Microenvironment in Cancer Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1277, 127-141.	0.8	0
672	Cancer Molecular and Functional Imaging. , 2020, , 729-738.		0
673	Fabrication of Micro-Nano Bioactive Glass Scaffold Incorporated with Siglec-15 for Bone Repair and Postoperative Treatment of Osteosarcoma. <i>Science of Advanced Materials</i> , 2021, 13, 1445-1451.	0.1	2
674	Strain-specific Differences in the Effects of Lymphocytes on the Development of Insulin Resistance and Obesity in Mice. <i>Comparative Medicine</i> , 2018, 68, 15-24.	0.4	1
675	Zeb1 expression by tumor or stromal cells is associated with spatial distribution patterns of CD8+ tumor-infiltrating lymphocytes: a hypothesis-generating study on 113 triple negative breast cancers. <i>American Journal of Cancer Research</i> , 2020, 10, 3370-3381.	1.4	1
676	Clinical determinants of relapse following CAR-T therapy for hematologic malignancies: Coupling active strategies to overcome therapeutic limitations. <i>Current Research in Translational Medicine</i> , 2022, 70, 103320.	1.2	9
677	Ferroptosis: The Silver Lining of Cancer Therapy. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 765859.	1.8	28
678	ACSL4 Expression Is Associated With CD8+ T Cell Infiltration and Immune Response in Bladder Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 754845.	1.3	8
679	A Ferroptosis-Related Prognostic Risk Score Model to Predict Clinical Significance and Immunogenic Characteristics in Glioblastoma Multiforme. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-30.	1.9	18
680	Simultaneous delivery of immune stimulatory gene and checkpoint blocker via targeted nanoparticles to strengthen antitumor immunity. <i>Materials Today Nano</i> , 2022, 17, 100151.	2.3	5
681	Transdermal Drug Delivery: A Step towards Treatment of Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2022, 17, 253-267.	0.8	6
682	Comprehensive Molecular Analyses of a Macrophages-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and LASSO Algorithm. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
683	Nanomaterials with changeable physicochemical property for boosting cancer immunotherapy. <i>Journal of Controlled Release</i> , 2022, 342, 210-227.	4.8	16

#	ARTICLE	IF	CITATIONS
684	Prognostic Value and Correlation With Tumor Immune Infiltration of a Novel Metabolism-Related Gene Signature in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 757791.	1.3	4
685	Ferroptosis Mediation Patterns Reveal Novel Tool to Implicate Immunotherapy and Multi-Omics Characteristics in Bladder Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 791630.	1.8	6
686	Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer. <i>BMC Cancer</i> , 2022, 22, 44.	1.1	8
687	Endocrine and Neuroendocrine Tumors Special Issueâ€”Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?. <i>Cancers</i> , 2022, 14, 467.	1.7	18
688	Recent advances in nanomedicines for photodynamic therapy (PDT)-driven cancer immunotherapy. <i>Theranostics</i> , 2022, 12, 434-458.	4.6	154
689	Emerging strategies for biomaterial-assisted cancer immunotherapy. <i>Korean Journal of Chemical Engineering</i> , 2022, 39, 227-240.	1.2	1
690	Managing GSH elevation and hypoxia to overcome resistance of cancer therapies using functionalized nanocarriers. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 67, 103022.	1.4	3
691	The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies. <i>Frontiers in Immunology</i> , 2021, 12, 807895.	2.2	20
692	A light-driven dual-nanotransformer with deep tumor penetration for efficient chemo-immunotherapy. <i>Theranostics</i> , 2022, 12, 1756-1768.	4.6	27
693	Tumor-derived extracellular vesicles: Potential tool for cancer diagnosis, prognosis, and therapy. <i>Saudi Journal of Biological Sciences</i> , 2022, 29, 2063-2071.	1.8	12
694	In situ T-cell transfection by anti-CD3-conjugated lipid nanoparticles leads to T-cell activation, migration, and phenotypic shift. <i>Biomaterials</i> , 2022, 281, 121339.	5.7	36
695	Recent Advances of Mesoporous Silica as a Platform for Cancer Immunotherapy. <i>Biosensors</i> , 2022, 12, 109.	2.3	16
696	Ferroptosis in cancer and cancer immunotherapy. <i>Cancer Communications</i> , 2022, 42, 88-116.	3.7	179
697	Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy. <i>Cancer Cell</i> , 2022, 40, 255-276.	7.7	45
698	Immunotherapy in the Treatment of Advanced Colorectal Cancer. , 2022, , 113-137.		0
699	Tumor microenvironment-regulated nanoplatforms for the inhibition of tumor growth and metastasis in chemo-immunotherapy. <i>Journal of Materials Chemistry B</i> , 2022, 10, 3637-3647.	2.9	6
700	A combination therapy of oncolytic viruses and chimeric antigen receptor T cells: a mathematical model proof-of-concept. <i>Mathematical Biosciences and Engineering</i> , 2022, 19, 4429-4457.	1.0	8
702	The role of the CRISPRâ€”Cas system in cancer drug development: Mechanisms of action and therapy. <i>Biotechnology Journal</i> , 2022, 17, e2100468.	1.8	6

#	ARTICLE	IF	CITATIONS
703	Large cohort humanized NPI mice reconstituted with CD34 <sup>+</sup> hematopoietic stem cells are feasible for evaluating preclinical cancer immunotherapy. <i>FASEB Journal</i> , 2022, 36, e22244.	0.2	4
704	Boosting Tumor Immunotherapy by Bioactive Nanoparticles via Ca <sup>2+</sup> Interference Mediated TME Reprogramming and Specific PD-L1 Depletion. <i>Advanced Functional Materials</i> , 2022, 32, .	7.8	32
705	TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer. <i>Frontiers in Immunology</i> , 2022, 13, 832230.	2.2	13
706	Targeting the PSGL-1 Immune Checkpoint Promotes Immunity to PD-1 <sup>hi</sup> Resistant Melanoma. <i>Cancer Immunology Research</i> , 2022, 10, 612-625.	1.6	12
707	Exploration of Novel Pathways Underlying Irreversible Electroporation Induced Anti-Tumor Immunity in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 853779.	1.3	6
708	Direct and indirect engagement of dendritic cell function by antibodies developed for cancer therapy. <i>Clinical and Experimental Immunology</i> , 2022, 209, 64-71.	1.1	5
709	<sc>SCI</sc>: A Bayesian adaptive phase I<sc>II</sc> dose-finding design accounting for <sc>semi</sc>-competing risks outcomes for immunotherapy trials. <i>Pharmaceutical Statistics</i> , 2022, 21, 960-973.	0.7	5
710	Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 849759.	2.2	4
711	Irradiation immunity interactions. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2022, 66, 519-535.	0.9	2
712	Association of the Microbiota and Pancreatic Cancer: Opportunities and Limitations. <i>Frontiers in Immunology</i> , 2022, 13, 844401.	2.2	15
713	Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer. <i>Journal of Biological Chemistry</i> , 2022, 298, 101817.	1.6	15
714	Tiltsotolimod: an investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma. <i>Expert Opinion on Investigational Drugs</i> , 2022, 31, 1-13.	1.9	8
715	Immunogenic Cell Death Amplified by Blockage of IDO1 Pathway Based on Charge-Switchable Nanoparticles for Elevated Cancer Immunotherapy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
716	STING and TLR7/8 agonists-based nanovaccines for synergistic antitumor immune activation. <i>Nano Research</i> , 2022, 15, 6328-6339.	5.8	13
717	Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 2018.	1.7	15
732	Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	9
733	The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy. , 2022, 13, 491.		17
734	Computational Investigations on the Natural Small Molecule as an Inhibitor of Programmed Death Ligand 1 for Cancer Immunotherapy. <i>Life</i> , 2022, 12, 659.	1.1	4



#	ARTICLE	IF	CITATIONS
735	Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy. <i>Science Advances</i> , 2022, 8, eabi8075.	4.7	21
736	Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies. <i>ACS Central Science</i> , 2022, 8, 590-602.	5.3	15
737	PD-L1 expression in gastric carcinoma - a biomarker for immunotherapy. <i>Biomedicine (India)</i> , 2022, 42, 383-387.	0.1	0
738	Change in Patients' Perceived Cognition Following Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 401.e1-401.e7.	0.6	10
739	Building Modern Cancer Care Services in Sub-Saharan Africa Based on a Clinical-Research Care Model. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 423-428.	1.8	3
741	Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	5
742	Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. <i>Molecules</i> , 2022, 27, 3454.	1.7	5
743	Recent Applications of Artificial Intelligence from Histopathologic Image-Based Prediction of Microsatellite Instability in Solid Cancers: A Systematic Review. <i>Cancers</i> , 2022, 14, 2590.	1.7	17
744	Comprehensive Molecular Analyses of a Macrophage-Related Gene Signature With Regard to Prognosis, Immune Features, and Biomarkers for Immunotherapy in Hepatocellular Carcinoma Based on WGCNA and the LASSO Algorithm. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	23
745	Immune-Enhancing Effects of Co-treatment With <i>Kalopanax pictus</i> Nakai Bark and <i>Nelumbo nucifera</i> Gaertner Leaf Extract in a Cyclophosphamide-Induced Immunosuppressed Rat Model. <i>Frontiers in Nutrition</i> , 2022, 9, .	1.6	3
746	Beyond GWAS: Could Genetic Differentiation within the Allograft Rejection Pathway Shape Natural Immunity to COVID-19?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6272.	1.8	3
748	Engineering CpG-ASO-Loaded Macrophages (CAP@M) for Synergistic Chemotherapy/Genetic Immunotherapy. <i>Advanced Healthcare Materials</i> , 2022, 11, .	3.9	8
749	High-Risk Acute Myeloid Leukemia: A Pediatric Prospective. <i>Biomedicines</i> , 2022, 10, 1405.	1.4	1
750	Overcome tumor relapse in CAR T cell therapy. <i>Clinical and Translational Oncology</i> , 0, , .	1.2	2
751	Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	33
752	Prediction of Prognosis in Patients with Hepatocellular Carcinoma Based on Molecular Subtypes of Immune Genes. <i>Gastroenterology Research and Practice</i> , 2022, 2022, 1-14.	0.7	0
753	Development and validation of a prognostic model for esophageal carcinoma based on immune microenvironment using system bioinformatics. <i>Cancer Medicine</i> , 0, , .	1.3	1
754	Effects of the combination of a monoclonal agonistic mouse anti-OX40 antibody and toll-like receptor agonists: Unmethylated CpG and LPS on an MB49 bladder cancer cell line in a mouse model. <i>PLoS ONE</i> , 2022, 17, e0270802.	1.1	2

#	ARTICLE	IF	CITATIONS
755	Blockage of the IDO1 pathway by charge-switchable nanoparticles amplifies immunogenic cell death for enhanced cancer immunotherapy. <i>Acta Biomaterialia</i> , 2022, 150, 353-366.	4.1	19
756	Mechanistic insights into the rational design of masked antibodies. <i>MAbs</i> , 2022, 14, .	2.6	4
757	Receptor–ligand pair typing and prognostic risk model for papillary thyroid carcinoma based on single-cell sequencing. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
758	Metal complex-based liposomes: Applications and prospects in cancer diagnostics and therapeutics. <i>Journal of Controlled Release</i> , 2022, 348, 1066-1088.	4.8	19
759	Neutrophils, functions beyond host defense. <i>Cellular Immunology</i> , 2022, 379, 104579.	1.4	5
760	Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	0
761	Physical and Chemical Cues at the Nano–Bio Interface for Immunomodulation. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	4
762	Physical and Chemical Cues at Nano–Bio Interface for Immunomodulation. <i>Angewandte Chemie</i> , 0, , .	1.6	0
763	Injectable Nanoparticle–Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies. <i>Advanced Science</i> , 2022, 9, .	5.6	11
764	Immuno-PET Monitoring of Lymphocytes Using the CD8-Specific Antibody REGN5054. <i>Cancer Immunology Research</i> , 2022, 10, 1190-1209.	1.6	2
765	Engineered Bacterial Outer Membrane Vesicles as Controllable Two-Way Adaptors to Activate Macrophage Phagocytosis for Improved Tumor Immunotherapy. <i>Advanced Materials</i> , 2022, 34, .	11.1	48
766	Purinergic receptors are a key bottleneck in tumor metabolic reprogramming: The prime suspect in cancer therapeutic resistance. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
767	A novel ferroptosis-related gene prognostic index for prognosis and response to immunotherapy in patients with prostate cancer. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	7
768	Macrophages in melanoma: A double-edged sword and targeted therapy strategies (Review). <i>Experimental and Therapeutic Medicine</i> , 2022, 24, .	0.8	9
769	Application of mRNA Technology in Cancer Therapeutics. <i>Vaccines</i> , 2022, 10, 1262.	2.1	7
770	Target-triggered catalytic hairpin assembly activation of CRISPR/Cas12a for amplified detection of therapeutic monoclonal antibody. <i>Sensors and Actuators B: Chemical</i> , 2022, 372, 132578.	4.0	2
771	Bacterial extracellular vesicles-based therapeutic strategies for bone and soft tissue tumors therapy. <i>Theranostics</i> , 2022, 12, 6576-6594.	4.6	31
773	Cancer suppression by ferroptosis and its role in digestive system tumors. <i>World Chinese Journal of Digestology</i> , 2022, 30, 718-728.	0.0	0

#	ARTICLE	IF	CITATIONS
774	Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	17
775	Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 1217-1237.	1.3	7
776	LAG3 blockade coordinates with microwave ablation to promote CD8+ T cell-mediated anti-tumor immunity. <i>Journal of Translational Medicine</i> , 2022, 20, .	1.8	9
777	Nanosized drug delivery systems modulate the immunosuppressive microenvironment to improve cancer immunotherapy. <i>Acta Pharmacologica Sinica</i> , 2022, 43, 3045-3054.	2.8	9
778	Quantitative high-throughput analysis of tumor infiltrating lymphocytes in breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
780	Liposomal Drug Delivery Systems for Cancer Therapy: The Rotterdam Experience. <i>Pharmaceutics</i> , 2022, 14, 2165.	2.0	10
781	Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	2
782	The Anti-Tumor and Immunomodulatory Effects of PLGA-Based Docetaxel Nanoparticles in Lung Cancer: The Potential Involvement of Necroptotic Cell Death through Reactive Oxygen Species and Calcium Build-Up. <i>Vaccines</i> , 2022, 10, 1801.	2.1	2
783	Clinical implications of T cell exhaustion for cancer immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 775-790.	12.5	182
784	Nanohydroxyapatite Stimulates PD-L1 Expression to Boost Melanoma Combination Immunotherapy. <i>ACS Nano</i> , 2022, 16, 18921-18935.	7.3	3
785	Spatial and Quantitative Analysis of Tumor-Associated Macrophages: Intratumoral CD163-/PD-L1+ TAMs as a Marker of Favorable Clinical Outcomes in Triple-Negative Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13235.	1.8	6
786	Aggregation-Induced Emission Photosensitizer-Loaded Nano-Superartificial Dendritic Cells with Directly Presenting Tumor Antigens and Reversed Immunosuppression for Photodynamically Boosted Immunotherapy. <i>Advanced Materials</i> , 2023, 35, .	11.1	16
787	The microbiota and aging microenvironment in pancreatic cancer: Cell origin and fate. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188826.	3.3	5
788	Advances in immunotherapy for MMR proficient colorectal cancer. <i>Cancer Treatment Reviews</i> , 2022, 111, 102480.	3.4	11
789	Engineering white blood cell membrane-camouflaged nanocarriers for inflammation-related therapeutics. <i>Bioactive Materials</i> , 2023, 23, 80-100.	8.6	8
790	Multiple CAR-T cell therapy for acute B-cell lymphoblastic leukemia after hematopoietic stem cell transplantation: A case report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
791	Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13696.	1.8	0
792	Development of functional nanomedicines for tumor associated macrophages-focused cancer immunotherapy. <i>Theranostics</i> , 2022, 12, 7821-7852.	4.6	12

#	ARTICLE	IF	CITATIONS
793	Cytokine Therapy Combined with Nanomaterials Participates in Cancer Immunotherapy. <i>Pharmaceutics</i> , 2022, 14, 2606.	2.0	2
794	Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects. <i>Journal of Clinical Medicine</i> , 2022, 11, 6997.	1.0	1
795	Emerging Potential Mechanism and Therapeutic Target of Ferroptosis in PDAC: A Promising Future. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15031.	1.8	6
796	Rational combinations of targeted cancer therapies: background, advances and challenges. <i>Nature Reviews Drug Discovery</i> , 2023, 22, 213-234.	21.5	69
797	Development of <sup>89</sup> Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration. , 2022, 10, e004877.		2
799	Synergistic combination of targeted nano-nuclear-reactors and anti-PD-L1 nanobodies evokes persistent T cell immune activation for cancer immunotherapy. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	8
800	Multidisciplinary treatment of a patient with severe immune checkpoint inhibitor-induced colitis: A case report. <i>World Journal of Clinical Cases</i> , 0, 10, 13108-13114.	0.3	1
801	Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	14
802	Propolis anti-inflammatory effects on MAGE-1 and retinoic acid-treated dendritic cells and on Th1 and T regulatory cells. <i>Journal of Venomous Animals and Toxins Including Tropical Diseases</i> , 0, 29, .	0.8	1
803	A prognostic model incorporating inflammatory cells and cytokines for newly diagnosed multiple myeloma patients. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2583-2591.	1.9	1
804	Approaching the Dimerization Mechanism of Small Molecule Inhibitors Targeting PD-L1 with Molecular Simulation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 1280.	1.8	5
805	Progress in the application of hydrogels in immunotherapy of gastrointestinal tumors. <i>Drug Delivery</i> , 2023, 30, .	2.5	5
806	Engineered bacteria for augmented <i>in situ</i> tumor vaccination. <i>Biomaterials Science</i> , 2023, 11, 1137-1152.	2.6	6
807	Biomaterial-Based In Situ Cancer Vaccines. <i>Advanced Materials</i> , 0, , .	11.1	13
808	Biodegradable MnO <sub>2</sub> -based gene-engineered nanocomposites for chemodynamic therapy and enhanced antitumor immunity. <i>Materials Today Bio</i> , 2023, 18, 100531.	2.6	3
809	Efficacy and safety of CD22-specific and CD19/CD22-bispecific CAR-T cell therapy in patients with hematologic malignancies: A systematic review and meta-analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
810	Immunotherapy for Nasopharyngeal Cancer. , 2023, , 1-13.		0
811	Stimuli-responsive hydrogels for cancer immunotherapy. <i>Polymer Chemistry</i> , 2023, 14, 793-802.	1.9	3

#	ARTICLE	IF	CITATIONS
812	Molecular DNA dendron vaccines. Proceedings of the National Academy of Sciences of the United States of America, 2023, 120, .	3.3	4
813	Interrelation between Programmed Cell Death and Immunogenic Cell Death: Take Antitumor Nanodrug as an Example. Small Methods, 2023, 7, .	4.6	19
814	Trends and Characteristics of Potentially Preventable Emergency Department Visits Among Patients With Cancer in the US. JAMA Network Open, 2023, 6, e2250423.	2.8	18
815	Vesicular Antibodies: Shedding Light on Antibody Therapeutics with Cell Membrane Nanotechnology. Advanced Materials, 2023, 35, .	11.1	8
816	Current Landscape and Potential Challenges of Immune Checkpoint Inhibitors in Microsatellite Stable Metastatic Colorectal Carcinoma. Cancers, 2023, 15, 863.	1.7	6
817	Clinical Applications of Novel Delivery Routes of Immunotherapy Drugs and Vaccines. , 2023, , 1-25.		0
818	Highlights into historical and current immune interventions for cancer. International Immunopharmacology, 2023, 117, 109882.	1.7	2
819	Tratamento da leucemia linfÃ³ide aguda em crianÃ§as: uma revisÃ£o narrativa. Brazilian Journal of Development, 2023, 9, 13353-13369.	0.0	1
821	Immunotherapy for Hematological Cancers. , 2023, , 1-15.		0
822	The role of potential probiotic strains Lactobacillus reuteri in various intestinal diseases: New roles for an old player. Frontiers in Microbiology, 0, 14, .	1.5	11
823	Acoustofluidic assembly of primary tumor-derived organotypic cell clusters for rapid evaluation of cancer immunotherapy. Journal of Nanobiotechnology, 2023, 21, .	4.2	6
824	How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation. International Journal of Cancer, 2023, 153, 709-722.	2.3	3
825	Liver Cancer and the Curative Potential of Nanomedicine. , 2023, , 283-306.		0
826	Recent advances in hydrogels for preventing tumor recurrence. Biomaterials Science, 2023, 11, 2678-2692.	2.6	4
827	Tumor-infiltrating lymphocyte therapy: an overview. Journal of Applied Biotechnology & Bioengineering, 2023, 10, 32-35.	0.0	0
828	A Convergent Synthesis of HPK1 Inhibitor GNE-6893 via Palladium-Catalyzed Functionalization of a Tetrasubstituted Isoquinoline. Organic Process Research and Development, 2023, 27, 523-529.	1.3	2
829	Immune Strategies for Gastrointestinal Cancer: HCC. , 2023, , 163-176.		0
830	Harnessing Nanomaterials for Cancer Sonodynamic Immunotherapy. Advanced Materials, 2023, 35, .	11.1	33

#	ARTICLE	IF	CITATIONS
831	Exploring immune interactions in triple negative breast cancer: IL-1 $\beta$ inhibition and its therapeutic potential. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	5
832	Clinical factors affecting the long-term survival of breast cancer patients. <i>Journal of International Medical Research</i> , 2023, 51, 030006052311640.	0.4	0
833	Rheumatological adverse events secondary to immune checkpoint inhibitors. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2023, 19, 215-222.	0.2	0
834	Structure-Activity Relationship Studies Based on Quinazoline Derivatives as EGFR Kinase Inhibitors (2017-ĀPresent). <i>Pharmaceuticals</i> , 2023, 16, 534.	1.7	7
835	Evidence of Association between CTLA-4 Gene Polymorphisms and Colorectal Cancers in Saudi Patients. <i>Genes</i> , 2023, 14, 874.	1.0	2
836	Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation. <i>Journal of Controlled Release</i> , 2023, 357, 531-544.	4.8	7
846	RĀcepteurs lymphocytaires et surveillance immunitaire. , 2023, , 139-146.		0
853	Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment. , 2023, , 327-380.		0
855	Acute Kidney Injury in Oncology. , 2023, , .		0
861	Disentangling the roles of aneuploidy, chromosomal instability and tumour heterogeneity in developing resistance to cancer therapies. <i>Chromosome Research</i> , 2023, 31, .	1.0	2
866	Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics. <i>Clinical and Experimental Medicine</i> , 2023, 23, 4297-4322.	1.9	2
870	Therapeutic Potential of Nanocrystals for Targeting Lymphoid Carcinoma. , 2023, , 1-21.		0
872	Potential of Biotechnology in Cancer Management. , 2023, , 9-44.		0
878	Harnessing biomaterial architecture to drive anticancer innate immunity. <i>Journal of Materials Chemistry B</i> , 2023, 11, 10982-11005.	2.9	0
881	Effects of Chemotherapy on the Immune System: Implications for Cancer Treatment and Patient Outcomes. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 0, , .	1.4	1
886	Editorial: Community series in the role of angiogenesis and immune response in tumor microenvironment of solid tumor: volume II. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
899	Decipher the role of cancer stem cells in colorectal cancer based on molecular pathology and its clinical significance. , 2024, , 533-555.		0
906	Immune-oncological drug ipilimumab. , 2024, , 143-157.		0

#	ARTICLE	IF	CITATIONS
909	Case Report: Two cases of advanced primary cardiac angiosarcoma treated with anlotinib and a retrospective analysis of the literature. <i>Frontiers in Cardiovascular Medicine</i> , 0, 11, .	1.1	0